Appendix I. Excluded Studies

1. Abstracts for the 24th Conference of the Spanish Society of Clinical Pharmacology, Translating Science to the Art of Therapeutics. *Basic & Clinical Pharmacology & Toxicology*. 2011;109(5). Exclude: Publication type-conference abstract.

2. Abdel Aziz MH, Sidhu PS, Liang A, et al. Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition. *Journal of Medicinal Chemistry*. 2012;55(15):6888-6897. Exclude: Publication type-not randomized control trial.

3. Abohelaika S, Wynne H, Avery P, Kamali F. Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. *J Thromb Haemost*. 2015;13(8):1436-1440. Exclude: Publication type-not randomized control trial.

4. Abohelaika S, Wynne H, Cope L, Kamali F. The impact of genetics on the management of patients on warfarin awaiting surgery. *Age & Ageing*. 2015;44(4):721-722. Exclude: Publication type-case report.

5. Adcock DM, Koftan C, Crisan D, Kiechle FL. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. *Archives of Pathology & Laboratory Medicine*. 2004;128(12):1360-1363. Exclude: Date.

6. Ahlehoff O, Hansen PR. [Cardiovascular pharmacogenomics]. *Ugeskrift for Laeger*. 2009;171(17):1405-1407. Exclude: Not English.

7. Ahnstrom J, Andersson HM, Hockey V, et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. *Blood*. 2012;120(25):5059-5062. Exclude: Publication type-not randomized control trial.

8. Al-Badri A, Spyropoulos AC. Treatment and long-term management of venous thromboembolism. *Clinics in Laboratory Medicine*. 2014;34(3):519-536. Exclude: Not intervention of interest.

9. Alcocer L. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. *American Journal of Cardiovascular Drugs*. 2016;16(3):171-182. Exclude: Publication type-not systematic review.

10. Allemang MT, Rajani RR, Nelson PR, Hingorani A, Kashyap VS. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. *Annals of Vascular Surgery*. 2013;27(1):62-67. Exclude: Publication type-not randomized control trial.

11. Al-Metwali B, Yong S, O'Hare LJ, et al. Personalised Warfarin dosing in children after congenital heart surgery: a randomised, prospective, cross-over, pilot study at Glenfield hospital, Leicester. *Heart Conference: British congenital cardiac association annual meeting, BCCA*. 2017;103. Exclude: Publication type-conference abstract.

12. Alvan G. Ethnic differences in reactions to drugs and xenobiotics. Other protein variants with pharmacogenetic consequences: albumin and orosomucoid. *Progress in Clinical & Biological Research*. 1986;214:345-355. Exclude: Not intervention of interest.

13. Alvarellos ML, Sangkuhl K, Daneshjou R, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for CYP4F2. *Pharmacogenetics and Genomics*. 2015;25(1):41-47. Exclude: Publication type-commentary.

14. Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. *BioMed Research International*. 2013;2013:315980. Exclude: Publication type-not randomized control trial.

15. Alzubiedi S, Saleh MI. Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. *Journal of Cardiovascular Pharmacology*. 2016;67(1):86-92. Exclude: Publication type-not randomized control trial.

16. American College of O, Gynecologists Committee on G. ACOG Committee Opinion No. 488: Pharmacogenetics. *Obstetrics & Gynecology*. 2011;117(5):1240-1241. Exclude: Not intervention of interest.

17. Aminkeng F. Using pharmacogenetics in real time to guide therapy: the warfarin example. *Clinical Genetics*. 2014;85(6):533-534. Exclude: Publication type-commentary.

18. An SH, Chang BC, Lee KE, Gwak HS. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. *Cardiovascular therapeutics*. 2015;33(6):324-328. Exclude: Publication type-not randomized control trial.

19. Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: are we there yet? *Stroke*. 2010;41(12):2997-3002. Exclude: Publication type-commentary.

20. Anderson DC, Jr. Pharmacogenomics and warfarin. *American Journal of Health-System Pharmacy*. 2009;66(2):121. Exclude: Publication type-commentary.

21. Anderson DC, Jr. More on pharmacogenomics and warfarin. *American Journal of Health-System Pharmacy*. 2009;66(14):1256-1257. Exclude: Publication type-letter.

22. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) [conference abstract]. *Circulation*. 2011;124(21 Suppl 1):Abstract 12310. Exclude: Publication type-conference abstract.

23. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). *Circulation*. 2012;125(16):1997-2005. Exclude: No comparator.

24. Andrew D. Warfarin dosing by genotype did not improve time in therapeutic range. *Annals of internal medicine*. 2014;160(6):JC8-JC10. Exclude: Publication type-conference abstract.

25. Anonymous. The clinical importance of pharmacogenetics. *California Medicine*. 1969;111(4):291-297. Exclude: Date.

26. Anonymous. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin. *Harvard Heart Letter*. 2007;18(4):1-2. Exclude: Publication type-commentary.

27. Anonymous. Warfarin-acetaminophen interaction. *Medical Letter on Drugs & Therapeutics*. 2008;50(1288):45. Exclude: Publication type-commentary.

28. Anonymous. Pharmacogenetic-based dosing of warfarin. *Medical Letter on Drugs & Therapeutics*. 2008;50(1286):39-40. Exclude: Publication type-letter.

29. Anonymous. Novel polymorphisms in CYP4F2 and VKORC1 may lead to adaptations to the warfarin-dosage algorithm. *Pharmacogenomics*. 2013;14(9):1003. Exclude: Publication type-commentary.

30. Anraku M, Kragh-Hansen U, Kawai K, et al. Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo. *Pharmaceutical Research*. 2003;20(4):684-692. Exclude: Date.

31. Ansell J. Personalizing health care--is this the right time for warfarin? *Journal of General Internal Medicine*. 2009;24(5):690-691. Exclude: Publication type-commentary.

32. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6 Suppl):160S-198S. Exclude: Publication type-not systematic review.

33. Anton AI, Cerezo-Manchado JJ, Padilla J, et al. Novel associations of VKORC1 variants with higher acenocoumarol requirements. *PLoS ONE [Electronic Resource]*. 2013;8(5):e64469. Exclude: Publication type-not randomized control trial.

34. Aomori T, Fujita Y, Obayashi K, et al. Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring. *Journal of Clinical Pharmacy & Therapeutics*. 2014;39(3):319-321. **Exclude: Publication type-not randomized control trial**.

35. Aomori T, Yamamoto K, Oguchi-Katayama A, et al. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2. *Clinical Chemistry*. 2009;55(4):804-812. Exclude: Publication type-not randomized control trial.

36. Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2004;24(6):720-726. Exclude: Not intervention of interest.

37. Arnold ML, Grond-Ginsbach C, Kloss M, et al. Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients. *Cerebrovascular Diseases*. 2009;28(5):468-471. Exclude: Publication type-not randomized control trial.

38. Arslanbekova SM, Sychev DA, Kazakov RE, Smirnov VV, Kuznetsova EV, Golukhova EZ. [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. *Kardiologiia.* 2013;53(12):21-24. Exclude: Not English.

39. Arwood MJ, Deng J, Drozda K, et al. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach. *Clinical Pharmacology & Therapeutics.* 2017;101(5):675-683. Exclude: Publication type-not randomized control trial.

40. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. *Lancet.* 2010;375(9725):1525-1535. Exclude: Publication type-not randomized control trial.

41. Au N, Rettie AE. Pharmacogenomics of 4-hydroxycoumarin anticoagulants. *Drug Metabolism Reviews.* 2008;40(2):355-375. Exclude: Publication type-commentary.

42. Avery PJ, Jorgensen A, Hamberg AK, et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. *Clinical Pharmacology & Therapeutics.* 2011;90(5):701-706. Exclude: No outcome of interest.

43. Bader LA, Elewa H. The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. *PLoS ONE [Electronic Resource].* 2016;11(12):e0168732. Exclude: Not intervention of interest.

44. Baglin T. Avoiding overanticoagulation: pharmacogenomics or pragmatism? *Thromb Haemost.* 2001;85(5):945-946. Exclude: Date.

45. Baglin TP. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions? *Clinical Advances in Hematology & Oncology.* 2003;1(11):656-657. Exclude: Date.

46. Baker WL, Chamberlin KW. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? *Clinical Pharmacology & Therapeutics.* 2014;96(1):17-19. Exclude: Publication type-commentary.

47. Baker WL, Johnson SG. Pharmacogenetics and oral antithrombotic drugs. *Current Opinion in Pharmacology.* 2016;27:38-42. Exclude: Publication type-commentary.

48. Baranova EV, Asselbergs FW, de Boer A, Maitland-van der Zee AH. The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation? *Current Molecular Medicine.* 2014;14(7):841-848. Exclude: Publication type-commentary.

49. Baranova EV, Verhoef TI, Asselbergs FW, de Boer A, Maitland-van der Zee AH. Genotype-guided coumarin dosing: where are we now and where do we need to go next? *Expert Opinion On Drug Metabolism & Toxicology.* 2015;11(4):509-522. Exclude: Publication type-commentary.

50. Baranova EV, Verhoef TI, Ragia G, et al. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. *J Thromb Haemost*. 2017;15(3):465-472. Exclude: No outcome of interest.

51. Baudhuin LM. Warfarin pharmacogenetics: ready for clinical utility? *Clinical Laboratory Science*. 2009;22(3):151-155. Exclude: Publication type-commentary.

52. Baudhuin LM, Langman LJ, O'Kane DJ. Translation of pharmacogenetics into clinically relevant testing modalities. *Clinical Pharmacology & Therapeutics*. 2007;82(4):373-376. Exclude: Publication type-commentary.

53. Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. *International Journal of Clinical Pharmacy*. 2012;34(6):837-844. Exclude: Not intervention of interest.

54. Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary OA. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. *Irish Journal of Medical Science*. 2014;183(2):161-172. Exclude: Publication type-not randomized control trial.

55. Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. *Blood*. 1998;92(8):2696-2706. Exclude: Date.

56. Becquemont L. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. *European Journal of Clinical Pharmacology*. 2008;64(10):953-960. Exclude: Publication type-commentary.

57. Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. *Pharmacogenomics*. 2009;10(6):961-969. Exclude: Publication type-commentary.

58. Becquemont L, Alfirevic A, Amstutz U, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. *Pharmacogenomics*. 2011;12(1):113-124. Exclude: Publication type-conference abstract.

59. Becquemont L, Verstuyft C, Jaillon P. [Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants]. *Bulletin de l Academie Nationale de Medecine*. 2006;190(1):37-49; discussion 50-33. Exclude: Date.

60. Begg EJ, Helsby NA, Jensen BP. Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. *Pharmacogenomics*. 2012;13(1):83-89. Exclude: Publication type-commentary.

61. Beier MT. Warfarin monitoring woes: a glimmer of hope with pharmacogenomics. *Journal of the American Medical Directors Association*. 2008;9(3):199-200. Exclude: Not intervention of interest.

62. Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. *Thromb Haemost*. 2008;100(6):1052-1057. Exclude: Not intervention of interest.

63. Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. *Trends in Pharmacological Sciences*. 2006;27(9):498-502. Exclude: Date.

64. Belley-Cote EP, Hanif H, D'Aragon F, et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation: a systematic review and meta-analysis. *Thromb Haemost*. 2015;114(4):768-777. Exclude: Individual studies from systematic review are included.

65. Belley-Cote EP, Whitlock RP, French B, Evaniew N, Kimmel SE. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: Meta-analysis of randomized controlled trials: Comment. *Thromb Res*. 2015;136(1):180-181. Exclude: Publication type-commentary.

66. Belley-Cote EP, Whitlock RP, French B, Evaniew N, Kimmel SE. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis: comment. *J Thromb Haemost*. 2015;13(6):1162-1164. Exclude: Publication type-commentary.

67. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. *Expert Opinion on Drug Safety*. 2018;17(1):25-37. Exclude: Publication type-commentary.

68. Benavides F, Grossman N, Poggi H, et al. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals]. *Revista Medica de Chile*. 2015;143(11):1369-1376. Exclude: Publication type-not randomized control trial.

69. Benusiglio PR, Desmeules J, de Moerloose P, Dayer P. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. *Revue Medicale Suisse*. 2007;3(124):2030. Exclude: Publication type-commentary.

70. Berinstein E, Levy A. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. *Expert Opinion On Drug Metabolism & Toxicology*. 2017;13(9):973-983. Exclude: Publication type-commentary.

71. Biss T, Hamberg AK, Avery P, Wadelius M, Kamali F. Warfarin dose prediction in children using pharmacogenetics information. *British Journal of Haematology*. 2012;159(1):106-109. Exclude: Publication type-letter.

72. Biss TT, Avery PJ, Brandao LR, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. *Blood*. 2012;119(3):868-873. Exclude: Not intervention of interest.

73. Biss TT, Avery PJ, Williams MD, Brandao LR, Grainger JD, Kamali F. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. *J Thromb Haemost*. 2013;11(2):373-375. Exclude: Publication type-letter.

74. Black SA, Cohen AT. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. *Thromb Haemost*. 2015;114(4):660-669. Exclude: Not intervention of interest.

75. Bolt G, Steenstrup TD, Kristensen C. All post-translational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII. *Thromb Haemost*. 2007;98(5):988-997. Exclude: Publication type-not randomized control trial.

76. Bon Homme M, Reynolds KK, Valdes R, Jr., Linder MW. Dynamic pharmacogenetic models in anticoagulation therapy. *Clinics in Laboratory Medicine*. 2008;28(4):539-552. Exclude: Publication type-commentary.

77. Bonou M, Kapelios CJ, Benetos G, et al. Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure. *Canadian Journal of Cardiology*. 2017;33(5):688.e685-688.e687. Exclude: Not intervention of interest.

78. Borkowski AA, Kardani A, Mastorides SM, Thomas LB. Warfarin pharmacogenomics: recommendations with available patented clinical technologies. *Recent Patents on Biotechnology*. 2014;8(2):110-115. Exclude: Publication type-commentary.

79. Borobia AM, Lubomirov R, Ramirez E, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. *PloS one*. 2012;7(7). Exclude: Not intervention of interest.

80. Borobia AMR, Ramirez E. Efficiency and effectiveness of the use of an acenocumarol pharmacogenetic dosing algorithm vs. usual care EN patients with venous thromboembolic disease (VTD) initiating oral anticoagulation: Study protocol for a multicentric randomized controlled trial. *Basic & Clinical Pharmacology & Toxicology*. 2009;109(33):2009-016643. Exclude: No outcome of interest.

81. Botton MR, Hutz MH, Suarez-Kurtz G. Influence of the CYP2C9 3 allele on the pharmacological interaction between warfarin and simvastatin. *Pharmacogenomics*. 2012;13(14):1557-1559; author reply 1561-1552. Exclude: Publication type-letter.

82. Bourel M, Ardaillou R. [Pharmacogenetics and pharmacogenomics]. *Bulletin de l Academie Nationale de Medecine*. 2006;190(1):9-22; discussion 22-23. Exclude: Date.

83. Bourgain C. [Genomics from bench to bedside: a change in perspective]. *M S-Medecine Sciences*. 2014;30 Spec No 2:14-17. Exclude: Not English.

84. Bradshaw EH. Third Annual Open Meeting of the UK Pharmacogenomics and Stratified Medicine Network Conference. *Pharmacogenomics*. 2015;16(8):775-778. Exclude: Publication type-conference abstract.

85. Breckenridge A. Pathophysiological factors influencing drug kinetics. *Acta Pharmacologica et Toxicologica*. 1971;29 Suppl 3:225-232. Exclude: Date.

86. Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. *JAMA*. 2013;310(2):189-198. Exclude: Not most recent systematic review.

87. Buclin T, Colombo S, Biollaz J. [Pharmacogenetic testing: soon before every prescription?]. *Revue Medicale Suisse*. 2008;4(165):1666-1670. Exclude: Publication type-commentary.

88. Bultas J. [Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?]. *Casopis Lekaru Ceskych*. 2010;149(10):476-481. Exclude: Publication type-commentary.

89. Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. *Methods in Molecular Biology*. 2010;632:99-124. Exclude: Publication type-commentary.

90. Burns LC, Orsini L, L'Italien G. Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use. *Value in Health*. 2013;16(6 Suppl):S16-19. Exclude: Publication type-commentary.

91. Bussey HI. The future landscape of anticoagulation management. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2011;31(12):1151-1155. Exclude: Publication type-commentary.

92. Bussey HI, Bussey M, Bussey-Smith KL, Frei CR. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2013;33(11):1136-1146. Exclude: Publication type-not randomized control trial.

93. Bussey HI, Wittkowsky AK, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2008;28(2):141-143. Exclude: Publication type-commentary.

94. Buzoianu AD, Trifa AP, Muresanu DF, Crisan S. Analysis of CYP2C9 2, CYP2C9 3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. *Journal of Cellular & Molecular Medicine*. 2012;16(12):2919-2924. Exclude: Publication type-not randomized control trial.

95. Byron KA, Dear AE. Genotype and adverse drug reactions to warfarin. *Medical Journal of Australia*. 2007;187(1):61-62. Exclude: Publication type-letter.

96. Caldwell MD, Berg RL, Zhang KQ, et al. Evaluation of genetic factors for warfarin dose prediction.[Erratum appears in Clin Med Res. 2007 Jun;5(2):142]. *Clinical Medicine & Research*. 2007;5(1):8-16. Exclude: Publication type-not randomized control trial.

97. Campello E, Spiezia L, Simioni P. Diagnosis and management of factor V Leiden. *Expert Review of Hematology*. 2016;9(12):1139-1149. Exclude: Publication type-commentary.

98. Campos-Outcalt D. Personalized medicine: the promise, the reality. *Journal of Family Practice*. 2007;56(8):621-626. Exclude: Publication type-not systematic review.

99. Capranzano P, Micciche E, D'Urso L, Privitera F, Tamburino C. Personalizing oral anticoagulant treatment in patients with atrial fibrillation. *Expert Review of Cardiovascular Therapy*. 2013;11(8):959-973. Exclude: Not intervention of interest.

100. Carcas AJ, Borobia AM, Velasco M, et al. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. *Trials [Electronic Resource].* 2012;13:239. Exclude: No outcome of interest.

101. Carleton B. Gene-based warfaring dosing. *Therapeutic Drug Monitoring.* 2010;32(3):332. Exclude: Publication type-commentary.

102. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. *Circulation.* 2011;124(23):2554-2559. Exclude: Publication type-commentary.

103. Carlquist JF, Horne BD, Mower C, et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. *J Thromb Thrombolys.* 2010;30(3):358-364. Exclude: Publication type-not randomized control trial.

104. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. *J Thromb Thrombolys.* 2006;22(3):191-197. Exclude: Publication type-not randomized control trial.

105. Carlquist JF, McKinney JT, Nicholas ZP, et al. Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing. *J Thromb Thrombolys.* 2008;26(1):1-7. Exclude: Not intervention of interest.

106. Carnes CA. What is the role of pharmacogenetics in optimization of warfarin dosing? *Trends in Cardiovascular Medicine.* 2015;25(1):42-43. Exclude: Publication type-commentary.

107. Cavallari LH. Tailoring drug therapy based on genotype. *Journal of Pharmacy Practice.* 2012;25(4):413-416. Exclude: Publication type-commentary.

108. Cavallari LH, Butler C, Langaee TY, et al. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy.* 2011;31(8):785-792. Exclude: Publication type-not randomized control trial.

109. Cavallari LH, Limdi NA. Warfarin pharmacogenomics. *Current Opinion in Molecular Therapeutics.* 2009;11(3):243-251. Exclude: Publication type-commentary.

110. Cavallari LH, Mason DL. Cardiovascular Pharmacogenomics--Implications for Patients With CKD. *Advances in Chronic Kidney Disease.* 2016;23(2):82-90. Exclude: Publication type-commentary.

111. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. *Blood Cells Molecules & Diseases.* 2011;46(2):147-150. Exclude: Publication type-not randomized control trial.

112. Cavallari LH, Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. *Clinical Pharmacology & Therapeutics.* 2014;96(1):22-24. Exclude: Publication type-commentary.

113. Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. *Future Cardiology*. 2012;8(4):563-576. Exclude: Publication type-commentary.

114. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2011;31(12):1192-1207. Exclude: Publication type-commentary.

115. Cavallari LH, Weitzel K. Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress. *Future Cardiology*. 2015;11(3):281-286. Exclude: Publication type-commentary.

116. Cen HJ, Zeng WT, Leng XY, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. *British Journal of Clinical Pharmacology*. 2010;70(2):234-240. Exclude: Publication type-not randomized control trial.

117. Cerezo-Manchado JJ, Roldan V, Corral J, et al. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. *Thromb Haemost*. 2016;115(1):117-125. Exclude: Not intervention of interest.

118. Cerezo-Manchado JJ, Rosafalco M, Anton AI, et al. Creating a genotype-based dosing algorithm for acenocoumarol steady dose. *Thromb Haemost*. 2013;109(1):146-153. Exclude: Publication type-not randomized control trial.

119. Chan SL, Chia KS, Wee HL. Informing the design of a discrete choice experiment for evaluating warfarin pharmacogenetic testing among Mandarin-speaking Chinese warfarin patients in Singapore: a mixed methods analysis. *Annals of the Academy of Medicine, Singapore*. 2014;43(4):235-237. Exclude: Publication type-letter.

120. Chan SL, Low JJ, Chia KS, Wee HL. Attitudes on warfarin pharmacogenetic testing in Chinese patients and public. *International Journal of Technology Assessment in Health Care*. 2014;30(1):113-120. Exclude: Publication type-not randomized control trial.

121. Chan SL, Samaranayake N, Ross CJ, et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. *Pharmacogenetics and Genomics*. 2016;26(1):28-39. Exclude: Not intervention of interest.

122. Chan SL, Suo C, Chia KS, Teo YY. The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. *Pharmacogenomics*. 2012;13(11):1247-1256. Exclude: Publication type-not randomized control trial.

123. Chan SL, Suo C, Lee SC, Goh BC, Chia KS, Teo YY. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. *Pharmacogenomics Journal*. 2012;12(4):312-318. Exclude: Publication type-not randomized control trial.

124. Chang M, Soderberg MM, Scordo MG, Tybring G, Dahl ML. CYP2C19 17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance

therapy. *European Journal of Clinical Pharmacology*. 2015;71(4):433-439. Exclude: Publication type-not randomized control trial.

125. Chappell JC, Dickinson G, Mitchell MI, Haber H, Jin Y, Lobo ED. Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study. *European Journal of Clinical Pharmacology*. 2012;68(3):239-247. Exclude: Not intervention of interest.

126. Chen C, Li S, Lu X, Tan B, Huang C, Qin L. High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9. *International Journal of Clinical & Experimental Pathology*. 2014;7(5):2558-2564. Exclude: Publication type-not randomized control trial.

127. Chen J, Shao L, Gong L, et al. A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. *PLoS ONE [Electronic Resource]*. 2014;9(8):e105250. Exclude: Publication type-not randomized control trial.

128. Chen W, Wu L, Liu X, et al. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement. *International Journal of Clinical Pharmacology & Therapeutics*. 2017;55(2):126-132. Exclude: Not intervention of interest.

129. Chern HD, Ueng TH, Fu YP, Cheng CW. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. *Clinica Chimica Acta*. 2006;367(1-2):108-113. Exclude: Not intervention of interest.

130. Chiba K. [Genetic polymorphism of the CYP2C subfamily]. *Nippon Yakurigaku Zasshi - Folia Pharmacologica Japonica*. 1998;112(1):15-21. Exclude: Date.

131. Chin PK, Vella-Brincat JW, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? *British Journal of Clinical Pharmacology*. 2012;74(5):734-740. Exclude: Publication type-commentary.

132. Cho HJ, On YK, Bang OY, et al. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. *Clinical Therapeutics*. 2011;33(10):1371-1380. Exclude: Not intervention of interest.

133. Cho SM, Lee KY, Choi JR, Lee KA. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. *Yonsei Medical Journal*. 2016;57(3):635-640. Exclude: Publication type-not randomized control trial.

134. Choi J, Kim HJ, Chang MH, Choi JR, Yoo JH. A rare splicing mutation in the PROS1 gene of a Korean patient with type I hereditary protein S deficiency. *Annals of Clinical & Laboratory Science*. 2011;41(4):397-400. Exclude: Publication type-case report.

135. Choi JR, Kim JO, Kang DR, et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. *Journal of Human Genetics*. 2011;56(4):290-295. Exclude: Publication type-not randomized control trial.

136. Chong HY, Saokaew S, Dumrongprat K, et al. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. *Thromb Res*. 2014;134(6):1278-1284. Exclude: Not appropriate setting.

137. Chouchane L, Mamtani R, Dallol A, Sheikh JI. Personalized medicine: a patient-centered paradigm. *Journal of Translational Medicine*. 2011;9:206. Exclude: Publication type-commentary.

138. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. *Journal of Clinical Investigation*. 1996;98(7):1619-1625. Exclude: Date.

139. Chua YA, Abdullah WZ, Yusof Z, Gan SH. A new nested allele-specific multiplex polymerase chain reaction method for haplotyping of VKORC1 gene to predict warfarin sensitivity. *BioMed Research International*. 2014;2014:316310. Exclude: Publication type-not randomized control trial.

140. Chua YA, Abdullah WZ, Yusof Z, Gan SH. VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately predict warfarin dose requirements in some Malaysian patients. *Turkish Journal of Medical Sciences*. 2015;45(4):913-918. Exclude: Publication type-not randomized control trial.

141. Ciccacci C, Falconi M, Paolillo N, et al. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. *Pharmacogenetics and Genomics*. 2011;21(6):344-346. Exclude: Publication type-case report.

142. Ciccacci C, Rufini S, Politi C, Novelli G, Forte V, Borgiani P. Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes. *Thromb Res*. 2015;136(2):367-370. Exclude: Publication type-not randomized control trial.

143. Cini M, Legnani C, Cosmi B, et al. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. *European Journal of Clinical Pharmacology*. 2012;68(8):1167-1174. Exclude: Publication type-not randomized control trial.

144. Clem JR. Warfarin dosing and genetic testing. *South Dakota Medicine: The Journal of the South Dakota State Medical Association*. 2008;61(4):138-139. Exclude: Not intervention of interest.

145. Cocco G, Jerie P. Cardiac pathology and modern therapeutic approach in Behcet disease. *Cardiology Journal*. 2014;21(2):105-114. Exclude: Publication type-commentary.

146. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. *Medical Decision Making*. 2010;30(3):328-340. Exclude: Not intervention of interest.

147. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. *Blood*. 2008;112(4):1022-1027. Exclude: Publication type-not randomized control trial.

148. Cortez-Dias N, Correia MJ, Coutinho A, Fernandes C, Diogo AN, Lopes MG. Pharmacogenetics and anticoagulant therapy: two cases of genetically determined response to

warfarin. *Revista Portuguesa de Cardiologia*. 2009;28(9):995-1004. Exclude: Publication type-case report.

149. Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. *Bioinformatics*. 2011;27(10):1384-1389. Exclude: Publication type-not randomized control trial.

150. Crawford DC, Ritchie MD, Rieder MJ. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. *Pharmacogenomics*. 2007;8(5):487-496. Exclude: Publication type-commentary.

151. Czogalla KJ, Biswas A, Wendeln AC, et al. Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. *Blood*. 2013;122(15):2743-2750. Exclude: Publication type-not randomized control trial.

152. Dahal K, Sharma SP, Fung E, et al. Meta-analysis of randomized controlled trials of genotype-guided vs standard dosing of warfarin. *Chest*. 2015;148(3):701-710. Exclude: Individual studies from systematic review are included.

153. Dai DP, Li CB, Wang SH, Geng PW, Hu GX, Cai JP. [Identification of a novel CYP2C9 gene mutation (1400T>C) and assessment of its enzymatic activity in vitro]. *Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]*. 2013;93(44):3537-3541. Exclude: Not English.

154. Daly AK. Individualized drug therapy. *Current Opinion in Drug Discovery & Development*. 2007;10(1):29-36. Exclude: Publication type-commentary.

155. Daly AK. Interview. Ann K Daly talks to Tarryn Greenberg, Commissioning Editor. *Pharmacogenomics*. 2008;9(11):1583-1584. Exclude: Publication type-commentary.

156. Daly AK. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. *Archives of Toxicology*. 2013;87(3):407-420. Exclude: Publication type-commentary.

157. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. *Pharmacogenetics*. 2003;13(5):247-252. Exclude: Date.

158. Dance A. Medical histories. *Nature*. 2016;537(7619):S52-53. Exclude: Publication type-not randomized control trial.

159. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. *Pharmacogenomics*. 2011;12(12):1663-1670. Exclude: Publication type-not randomized control trial.

160. Dandona S. Cardiovascular drugs and the genetic response. *Methodist DeBakey cardiovascular journal*. 2014;10(1):13-17. Exclude: Publication type-commentary.

161. Dandona S, Roberts R. Personalized cardiovascular medicine: status in 2012. *Canadian Journal of Cardiology*. 2012;28(6):693-699. Exclude: Publication type-commentary.

162. D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. *Blood Reviews*. 2008;22(3):127-140. Exclude: Publication type-commentary.

163. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. *Blood*. 2005;105(2):645-649. Exclude: Not intervention of interest.

164. Daneshjou R, Gamazon ER, Burkley B, et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. *Blood*. 2014;124(14):2298-2305. Exclude: Publication type-not randomized control trial.

165. Daneshjou R, Tatonetti NP, Karczewski KJ, et al. Pathway analysis of genome-wide data improves warfarin dose prediction. *BMC Genomics*. 2013;14 Suppl 3:S11. Exclude: Publication type-not randomized control trial.

166. Darilmaz Yuce G. [Effect of genetic variations on adjusting of warfarin dose]. *Tuberkuloz ve Toraks*. 2014;62(3):236-242. Exclude: Not English.

167. de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. *Molecular Diagnosis & Therapy*. 2014;18(6):675-683. Exclude: Publication type-not randomized control trial.

168. Della-Morte D, Guadagni F, Palmirotta R, et al. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. *Pharmacogenomics*. 2012;13(5):595-613. Exclude: Publication type-commentary.

169. Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. *Mutation Research*. 2005;573(1-2):180-194. Exclude: Date.

170. Deykin D. Warfarin revisited. *New England Journal of Medicine*. 1970;283(8):436. Exclude: Date.

171. Deykin D. Warfarin revisited. *New England Journal of Medicine*. 1970;282(26):1486. Exclude: Date.

172. Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL. Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy. *Clinical Pharmacology & Therapeutics*. 2017;102(5):805-814. Exclude: Not intervention of interest.

173. Di Fusco D, Ciccacci C, Rufini S, Forte V, Novelli G, Borgiani P. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses. *Thromb Res*. 2013;132(1):123-126. Exclude: Publication type-not randomized control trial.

174. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. *British Journal of Clinical Pharmacology*. 2007;64(1):14-26. Exclude: Not intervention of interest.

175. Dieckmann KP, Anheuser P, Gehrckens R, Aries SP, Ikogho R, Hollburg W. Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report. *BMC Urology*. 2015;15:21. **Exclude: Publication type-not randomized control trial**.

176. Dimatteo C, D'Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. *Thromb Res*. 2016;144:1-5. Exclude: Publication type-not randomized control trial.

177. Dirckx C, Donati MB, Iacoviello L. Pharmacogenetics: a molecular sophistication or a new clinical tool for cardiologists? *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*. 2000;1(10):662-666. Exclude: Date.

178. Djaffar-Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. *Genetic Testing & Molecular Biomarkers*. 2011;15(11):827-830. Exclude: Not intervention of interest.

179. Do EJ, Lenzini P, Eby CS, et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. *Pharmacogenomics Journal*. 2012;12(5):417-424. Exclude: No outcome of interest.

180. Dollery CT. Enzyme induction. *British Journal of Anaesthesia*. 1972;44(9):961-966. Exclude: Date.

181. Donohue MM, Tirschwell DL. Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel. *Current Neurology & Neuroscience Reports*. 2011;11(1):52-60. Exclude: Publication type-commentary.

182. Drew L. Pharmacogenetics: The right drug for you. *Nature*. 2016;537(7619):S60-62. Exclude: Publication type-not systematic review.

183. Drozda K, Labinov Y, Jiang R, et al. A pharmacogenetics service experience for pharmacy students, residents, and fellows. *American Journal of Pharmaceutical Education*. 2013;77(8):175. Exclude: Publication type-not randomized control trial.

184. Drozda K, Wong S, Patel SR, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. *Pharmacogenetics and Genomics*. 2015;25(2):73-81. Exclude: Publication type-not randomized control trial.

185. Duconge J, Ramos AS, Claudio-Campos K, et al. A novel admixture-based pharmacogenetic approach to refine warfarin dosing in caribbean hispanics. *PloS one*. 2016;11(1). Exclude: Not intervention of interest.

186. Dumas S, Rouleau-Mailloux E, Barhdadi A, et al. Validation of patient-reported warfarin dose in a prospective incident cohort study. *Pharmacoepidemiology & Drug Safety*. 2014;23(3):285-289. Exclude: Publication type-not randomized control trial.

187. Dumas TE, Hawke RL, Lee CR. Warfarin dosing and the promise of pharmacogenomics. *Current Clinical Pharmacology*. 2007;2(1):11-21. Exclude: Publication type-commentary.

188. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. *Clinical Pharmacology & Therapeutics.* 2010;87(6):735-742. Exclude: Not intervention of interest.

189. Dutton RJ, Wayman A, Wei JR, Rubin EJ, Beckwith J, Boyd D. Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin. *Proceedings of the National Academy of Sciences of the United States of America.* 2010;107(1):297-301. Exclude: Publication type-not randomized control trial.

190. Eby C. Warfarin pharmacogenetics: does more accurate dosing benefit patients? *Seminars in Thrombosis & Hemostasis.* 2012;38(7):661-666. Exclude: Publication type-commentary.

191. Eby CS. Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time. *Clinical Chemistry.* 2009;55(4):712-714. Exclude: Publication type-commentary.

192. Eckman MH, Greenberg SM, Rosand J. Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? *Journal of General Internal Medicine.* 2009;24(5):543-549. Exclude: Publication type-commentary.

193. Eckman MH, Wong LK, Soo YO, et al. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help? *Stroke.* 2008;39(12):3308-3315. Exclude: Publication type-commentary.

194. Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. *Molecular Diagnosis & Therapy.* 2013;17(6):381-390. Exclude: Publication type-not randomized control trial.

195. Elias DJ, Topol EJ. Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin. *European Journal of Human Genetics.* 2008;16(5):532-534. Exclude: Publication type-commentary.

196. Emery JD. Pharmacogenomic Testing and Warfarin: What Evidence Has the GIFT Trial Provided? *JAMA.* 2017;318(12):1110-1112. Exclude: Publication type-commentary.

197. Enchin H. Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine? *AMIA Annual Symposium Proceedings/AMIA Symposium.* 2009;2009:168-172. Exclude: Publication type-commentary.

198. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. *Current Drug Targets.* 2006;7(12):1641-1648. Exclude: Date.

199. Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? *Clinical Pharmacokinetics.* 2001;40(11):783-802. Exclude: Date.

200. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). *J Am Coll Cardiol.* 2010;55(25):2804-2812. Exclude: Not intervention of interest.

201. Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? *Pharmacoeconomics*. 2010;28(10):905-913. Exclude: Publication type-not systematic review.

202. Eriksson N, Wadelius M. Prediction of warfarin dose: why, when and how? *Pharmacogenomics*. 2012;13(4):429-440. Exclude: Publication type-commentary.

203. Eriksson N, Wallentin L, Berglund L, et al. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. *Pharmacogenomics*. 2016;17(13):1425-1439. Exclude: Publication type-not randomized control trial.

204. Eschenhagen T, Blankenberg S. [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]. *Internist*. 2013;54(2):147-148, 150-142, 154. Exclude: Not English.

205. Esmerian MO, Mitri Z, Habbal MZ, et al. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. *Journal of Clinical Pharmacology*. 2011;51(10):1418-1428. Exclude: Publication type-not randomized control trial.

206. Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. *Annual Review of Pharmacology & Toxicology*. 2012;52:79-99. Exclude: Publication type-commentary.

207. Ferder NS, Eby CS, Deych E, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. *J Thromb Haemost*. 2010;8(1):95-100. Exclude: Not intervention of interest.

208. Fichter B, Heintzelman T, Hurst S, Fitzsimmons D, Mailloux C. Clinical utility of pharmacogenetic testing in compounding pharmacy. *International Journal of Pharmaceutical Compound*. 2013;17(6):452-457. Exclude: Publication type-commentary.

209. Fields MC, Levine SR. Thrombophilias and stroke: diagnosis, treatment, and prognosis. *J Thromb Thrombolys*. 2005;20(2):113-126. Exclude: Date.

210. Finkelman BS, French B, Bershaw L, et al. Predicting prolonged dose titration in patients starting warfarin. *Pharmacoepidemiology & Drug Safety*. 2016;25(11):1228-1235. Exclude: Publication type-not randomized control trial.

211. Finkelman BS, French B, Bershaw L, Kimmel SE. Factors affecting time to maintenance dose in patients initiating warfarin. *Pharmacoepidemiology & Drug Safety*. 2015;24(3):228-236. Exclude: Publication type-not randomized control trial.

212. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. *Journal of the American College of Cardiology*. 2011;57(5):612-618. Exclude: Publication type-not randomized control trial.

213. Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR. Pharmacogenomics of anti-platelet and anti-coagulation therapy. *Current Cardiology Reports*. 2013;15(7):381. Exclude: Publication type-commentary.

214. Fischer BE, Schlokat U, Mitterer A, et al. Rational design, recombinant preparation, and in vitro and in vivo characterization of human prothrombin-derived hirudin antagonists. *Journal of Biological Chemistry*. 1996;271(39):23737-23742. Exclude: Date.

215. Fishbain DA, Fishbain D, Lewis J, et al. Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. *Pain Medicine*. 2004;5(1):81-93. Exclude: Date.

216. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. *Genetics in Medicine*. 2008;10(2):139-150. Exclude: Not intervention of interest.

217. Flora DR, Rettie AE, Brundage RC, Tracy TS. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites. *Journal of Clinical Pharmacology*. 2017;57(3):382-393. Exclude: Publication type-not systematic review.

218. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. *J Thromb Haemost*. 2014;12(9):1480-1487. Exclude: Individual studies from systematic review are included.

219. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis: reply. *J Thromb Haemost*. 2015;13(6):1164-1165. Exclude: Publication type-letter.

220. Francis B, Lane S, Pirmohamed M, Jorgensen A. A review of a priori regression models for warfarin maintenance dose prediction. *PLoS ONE [Electronic Resource]*. 2014;9(12):e114896. Exclude: Not intervention of interest.

221. Francis CW. New issues in oral anticoagulants. *Hematology*. 2008:259-265. Exclude: Not intervention of interest.

222. Freedman JE, Iafrati HF. Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease. *Revista Espanola de Cardiologia*. 2010;63(10):1123-1126. Exclude: Publication type-commentary.

223. French B, Joo J, Geller NL, et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. *Trials [Electronic Resource]*. 2010;11:108. Exclude: No outcome of interest.

224. French B, Wang L, Gage BF, Horenstein RB, Limdi NA, Kimmel SE. A systematic analysis and comparison of warfarin initiation strategies. *Pharmacogenetics and Genomics*. 2016;26(10):445-452. Exclude: No outcome of interest.

225. Friede K, Li J, Voora D. Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. *Clinical Chemistry*. 2017;63(1):177-185. Exclude: Publication type-not systematic review.

226. Frueh FW. On rat poison and human medicines: personalizing warfarin therapy. *Trends in Molecular Medicine*. 2012;18(4):201-205. Exclude: Publication type-commentary.

227. Fuchshuber-Moraes M, Perini JA, Rosskopf D, Suarez-Kurtz G. Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. *European Journal of Clinical Pharmacology*. 2009;65(8):789-793. Exclude: Publication type-not randomized control trial.

228. Fuesl HS. [Long-term anticoagulation in atrial fibrillation. Individualized therapy in the era of new oral anticoagulants]. *MMW Fortschritte der Medizin*. 2014;156(18):22-24. Exclude: Not English.

229. Fung E, Patsopoulos NA, Belknap SM, et al. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. *Seminars in Thrombosis & Hemostasis*. 2012;38(8):893-904. Exclude: Publication type-commentary.

230. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? *New England Journal of Medicine*. 2013;369(24):2345-2346. Exclude: Publication type-commentary.

231. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. *Pharmacogenetics*. 1995;5(6):389-392. Exclude: Date.

232. Fusaro VA, Patil P, Chi CL, Contant CF, Tonellato PJ. A systems approach to designing effective clinical trials using simulations. *Circulation*. 2013;127(4):517-526. Exclude: Publication type-not randomized control trial.

233. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.[Erratum appears in Clin Pharmacol Ther. 2008 Sep;84(3):430]. *Clinical Pharmacology & Therapeutics*. 2008;84(3):326-331. Exclude: Publication type-not randomized control trial.

234. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. *Thromb Haemost*. 2004;91(1):87-94. Exclude: Date.

235. Gage BF, Eby CS. Pharmacogenetics and anticoagulant therapy. *J Thromb Thrombolys*. 2003;16(1-2):73-78. Exclude: Date.

236. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. *J Thromb Thrombolys*. 2008;25(1):45-51. Exclude: Publication type-commentary.

237. Gage BF, Milligan PE. Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. *Thromb Res*. 2005;117(1-2):55-59; discussion 65-57. Exclude: Date.

238. Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. *Thromb Res*. 2014;134(3):537-544. Exclude: No outcome of interest.

239. Gak E, Halkin H. Shifting paradigms in the pharmacogenetics of warfarin. *Pharmacogenomics*. 2008;9(10):1373-1375. Exclude: Publication type-commentary.

240. Gan GG, Phipps ME, Ku CS, Teh A, Sangkar V. Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose. *International Journal of Hematology*. 2004;80(3):295-296. Exclude: Date.

241. Gan GG, Phipps ME, Lee MM, et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. *Annals of Hematology*. 2011;90(6):635-641. Exclude: Publication type-not randomized control trial.

242. Gandara E, Wells PS. Will there be a role for genotyping in warfarin therapy? *Current Opinion in Hematology*. 2010;17(5):439-443. Exclude: Publication type-commentary.

243. Gao L, He L, Luo J, et al. Extremely low warfarin dose in patients with genotypes of CYP2C9 3/ 3 and VKORC1-1639A/A. *Chinese Medical Journal*. 2011;124(17):2767-2770. Exclude: Publication type-case report.

244. Garcia AA, Reitsma PH. VKORC1 and the vitamin K cycle. *Vitamins & Hormones*. 2008;78:23-33. Exclude: Publication type-commentary.

245. Garcia D, Ageno W, Bussey H, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. *American Journal of Hematology*. 2009;84(9):579-583. Exclude: Publication type-commentary.

246. Garcia DA. Warfarin and pharmacogenomic testing: the case for restraint. *Clinical Pharmacology & Therapeutics*. 2008;84(3):303-305. Exclude: Publication type-commentary.

247. Garcia DA, Hylek E. Warfarin pharmacogenetics. *New England Journal of Medicine*. 2009;360(23):2474; author reply 2475. Exclude: Publication type-letter.

248. Garcia P, Ruiz W, Loza Munarriz C. Warfarin initiation nomograms for venous thromboembolism. *Cochrane Database of Systematic Reviews*. 2016(1). Exclude: Not intervention of interest.

249. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. *Pharmacological Reviews*. 2006;58(3):521-590. Exclude: Date.

250. Garg K, Cayne N, Jacobowitz G. Mechanical and pharmacologic catheter-directed thrombolysis treatment of severe, symptomatic, bilateral deep vein thrombosis with congenital absence of the inferior vena cava. *Journal of Vascular Surgery*. 2011;53(6):1707-1710. Exclude: Publication type-case report.

251. Geisen C, Luxembourg B, Watzka M, et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. *European Journal of Clinical Pharmacology*. 2011;67(4):371-381. Exclude: Not intervention of interest.

252. Geisler BP, Levin-Scherz JK. Additional factors that could improve cost-effectiveness of pharmacogenetic-guided dosing in warfarin therapy. *Annals of Internal Medicine*. 2009;151(1):71; author reply 71. Exclude: Publication type-letter.

253. Gemmati D, Burini F, Talarico A, et al. The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. *PLoS ONE [Electronic Resource]*. 2016;11(9):e0162084. Exclude: Not intervention of interest.

254. Gentry PR, Hack CE, Haber L, Maier A, Clewell HJ, 3rd. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. *Toxicological Sciences*. 2002;70(1):120-139. Exclude: Date.

255. George J, Doney A, Palmer CN, Lang CC. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin. *Cardiovascular therapeutics*. 2010;28(3):135-138. Exclude: Publication type-commentary.

256. Ghadam P, Sharifian R, Farsangi ZJ, Kianmehr Z, Lak M. CYP2C9 gene analysis of some Iranian hypersensitive patients to warfarin. *Pakistan Journal of Biological Sciences*. 2009;12(16):1160-1163. Exclude: Publication type-not randomized control trial.

257. Gillaizeau F, Chan E, Trinquart L, et al. Computerized advice on drug dosage to improve prescribing practice. *Cochrane Database of Systematic Reviews*. 2013(11). Exclude: Not intervention of interest.

258. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. *Journal of the American College of Cardiology*. 2010;55(25):2813-2815. Exclude: Publication type-commentary.

259. Giri AK, Khan NM, Grover S, et al. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. *Pharmacogenomics*. 2014;15(10):1337-1354. Exclude: Publication type-not randomized control trial.

260. Gladding P. Personalised medicine in New Zealand. *New Zealand Medical Journal*. 2008;121(1272):10-13. Exclude: Publication type-commentary.

261. Gladding PA. Clinical applications of pharmacogenetics: present and near future. *Cleveland Clinic Journal of Medicine*. 2013;80(8):477-482. Exclude: Publication type-commentary.

262. Glurich I, Berg RL, Burmester JK. Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements? *Clinical Medicine & Research*. 2013;11(2):73-79. Exclude: Not intervention of interest.

263. Glurich I, Burmester JK, Caldwell MD. Understanding the pharmacogenetic approach to warfarin dosing. *Heart Failure Reviews*. 2010;15(3):239-248. Exclude: Publication type-commentary.

264. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. *British Journal of Clinical Pharmacology*. 2001;52(4):349-355. Exclude: Date.

265. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. *Pharmacogenetics*. 1994;4(6):285-299. Exclude: Date.

266. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. *Canadian Journal of Cardiology*. 2013;29(7 Suppl):S24-33. Exclude: Publication type-commentary.

267. Gong IY, Schwarz UI, Crown N, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. *PLoS ONE [Electronic Resource]*. 2011;6(11):e27808. Exclude: Publication type-not randomized control trial.

268. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. *Blood*. 2011;118(11):3163-3171. Exclude: Publication type-not randomized control trial.

269. Gonzalez Della Valle A, Khakharia S, Glueck CJ, et al. VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study. *Clinical Orthopaedics & Related Research*. 2009;467(7):1773-1780. Exclude: Publication type-not randomized control trial.

270. Gonzalez-Conejero R, Corral J, Roldan V, et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. *J Thromb Haemost*. 2007;5(8):1701-1706. Exclude: Publication type-not randomized control trial.

271. Gorbunova EV. [Approaches for prescribing anticoagulant therapy to patients with prosthetic heart valves]. *Klinicheskaia Meditsina*. 2013;91(2):49-52. Exclude: Publication type-commentary.

272. Goto S. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy? *Circulation Journal*. 2010;74(5):850-851. Exclude: Publication type-commentary.

273. Gotsman I, Ezra O, Hirsh Raccah B, Admon D, Lotan C, Dekeyser Ganz F. Patient-Specific Tailored Intervention Improves INR Time in Therapeutic Range and INR Variability in Heart Failure Patients. *American Journal of Medicine*. 2017;130(8):982-989. Exclude: Not intervention of interest.

274. Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. *J Thromb Haemost*. 2017;15(2):273-283. Exclude: Not intervention of interest.

275. Goulding R, Dawes D, Price M, Wilkie S, Dawes M. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. *Brit J Clin Pharmaco*. 2015;80(4):868-877. Exclude: Individual studies from systematic review are included.

276. Greer IA. Exploring the role of low-molecular-weight heparins in pregnancy. *Seminars in Thrombosis & Hemostasis*. 2002;28 Suppl 3:25-31. Exclude: Date.

277. Grice GR, Milligan PE, Eby C, Gage BF. Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive. *J Thromb Haemost*. 2008;6(1):207-209. Exclude: Publication type-letter.

278. Grossi E, Podda GM, Pugliano M, et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. *Pharmacogenomics.* 2014;15(1):29-37. Exclude: Publication type-not randomized control trial.

279. Grzesiak A, Buczek O, Petry I, Szewczuk Z, Otlewski J. Inhibition of serine proteinases from human blood clotting system by squash inhibitor mutants. *Biochimica et Biophysica Acta.* 2000;1478(2):318-324. Exclude: Date.

280. Gschwind L, Rollason V, Boehlen F, et al. P-glycoprotein: a clue to vitamin K antagonist stabilization. *Pharmacogenomics.* 2015;16(2):129-136. Exclude: Not intervention of interest.

281. Guessous I, Gwinn M, Yu W, Yeh J, Clyne M, Khoury MJ. Trends in pharmacogenomic epidemiology: 2001-2007. *Public Health Genomics.* 2009;12(3):142-148. Exclude: Publication type-not systematic review.

282. Gul EE, Altunbas G, Kayrak M, Ozdemir K. "The end of good luck''--long-term survival without anticoagulation: a case report and review of the literature. *Clinical & Applied Thrombosis/Hemostasis.* 2012;18(2):222-224. Exclude: Publication type-case report.

283. Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. *American Journal of Health-System Pharmacy.* 2009;66(2):123-133. Exclude: Publication type-commentary.

284. Gurwitz JH. Pharmacogenomics: is this the final chapter in the remarkable story of warfarin? *Journal of the American Medical Directors Association.* 2011;12(9):613-614. Exclude: Publication type-commentary.

285. Hadjipanagi D, Chrysanthou S, Voskarides K, Deltas C. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population. *BMC Research Notes.* 2014;7:123. Exclude: Publication type-not randomized control trial.

286. Haeusler KG, Wilson D, Fiebach JB, Kirchhof P, Werring DJ. Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives. *Heart.* 2014;100(18):1408-1413. Exclude: Publication type-commentary.

287. Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. *Heart.* 2005;91(5):563-564. Exclude: Date.

288. Hamberg AK, Friberg LE, Hanseus K, et al. Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.[Erratum appears in Eur J Clin Pharmacol. 2013 Sep;69(9):1737]. *European Journal of Clinical Pharmacology.* 2013;69(6):1275-1283. Exclude: Not intervention of interest.

289. Hamberg AK, Wadelius M. Pharmacogenetics-based warfarin dosing in children. *Pharmacogenomics.* 2014;15(3):361-374. Exclude: Publication type-commentary.

290. Hamberg AK, Wadelius M, Friberg LE, Biss TT, Kamali F, Jonsson EN. Characterizing variability in warfarin dose requirements in children using modelling and simulation. *British Journal of Clinical Pharmacology.* 2014;78(1):158-169. Exclude: Publication type-not randomized control trial.

291. Hanada K, Tochikura N, Ogata H. Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. *Biological & Pharmaceutical Bulletin*. 2007;30(8):1593-1595. Exclude: Publication type-not randomized control trial.

292. Hansen NT, Brunak S, Altman RB. Generating genome-scale candidate gene lists for pharmacogenomics. *Clinical Pharmacology & Therapeutics*. 2009;86(2):183-189. Exclude: Publication type-not randomized control trial.

293. Harada T, Ariyoshi N, Shimura H, et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm. *Thromb Res*. 2010;126(3):183-190. Exclude: Publication type-not randomized control trial.

294. Harrington DJ, Gorska R, Wheeler R, et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. *J Thromb Haemost*. 2008;6(10):1663-1670. Exclude: Not intervention of interest.

295. Hatch E, Wynne H, Avery P, Wadelius M, Kamali F. Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients. *J Thromb Haemost*. 2008;6(6):1038-1040. Exclude: Publication type-letter.

296. Hatta FH, Lundblad M, Ramsjo M, et al. Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. *Omics a Journal of Integrative Biology*. 2015;19(6):346-353. Exclude: Publication type-not randomized control trial.

297. Hawcutt DB, Ghani AA, Sutton L, et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. *Pharmacogenomics Journal*. 2014;14(6):542-548. Exclude: Publication type-not randomized control trial.

298. Hayashi H. [Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis]. *Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan*. 2013;133(10):1079-1085. Exclude: Not English.

299. Hayden EC. Cardiovascular disease gets personal. *Nature*. 2009;460(7258):940-941. Exclude: Publication type-commentary.

300. Hazai E, Visy J, Fitos I, Bikadi Z, Simonyi M. Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. *Bioorganic & Medicinal Chemistry*. 2006;14(6):1959-1965. Exclude: Date.

301. He SM, Zhou ZW, Li XT, Zhou SF. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. *Current Medicinal Chemistry*. 2011;18(5):667-713. Exclude: Publication type-commentary.

302. Helft G. [The best of thrombosis in 2005]. *Archives des Maladies du Coeur et des Vaisseaux*. 2006;99 Spec No 1(1):23-28. Exclude: Date.

303. Heller F. Genetics/genomics and drug effects. *Acta Clinica Belgica*. 2013;68(2):77-80. Exclude: Publication type-commentary.

304. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. *Thromb Haemost*. 2006;95(5):782-787. Exclude: Not intervention of interest.

305. Hernandez W, Aquino-Michaels K, Drozda K, et al. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. *Translational Research: The Journal Of Laboratory & Clinical Medicine*. 2015;165(6):651-657. Exclude: Publication type-not randomized control trial.

306. Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. *Pharmacogenomics Journal*. 2014;14(3):223-228. Exclude: Publication type-not randomized control trial.

307. Herve F, Gomas E, Duche JC, Tillement JP. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. *British Journal of Clinical Pharmacology*. 1993;36(3):241-249. Exclude: Date.

308. Hijazi N, Abu Fanne R, Abramovitch R, et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. *Blood*. 2015;125(16):2558-2567. Exclude: Not intervention of interest.

309. Hill CE, Duncan A. Overview of pharmacogenetics in anticoagulation therapy. *Clinics in Laboratory Medicine*. 2008;28(4):513-524. Exclude: Publication type-commentary.

310. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. *Pharmacogenetics*. 2004;14(8):539-547. Exclude: Publication type-not randomized control trial.

311. Hinneburg I. [Individualized medicine between expectations and reality]. *Medizinische Monatsschrift fur Pharmazeuten*. 2011;34(6):212-214. Exclude: Not English.

312. Hirai K, Yamada Y, Hayashi H, et al. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. *Thromb Res*. 2015;135(5):861-866. Exclude: Publication type-not randomized control trial.

313. Hishida M, Inokawa Y, Takano N, et al. Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array. *Journal of Surgical Research*. 2015;195(2):444-453. Exclude: Publication type-not randomized control trial.

314. Ho WK, Hankey GJ, Eikelboom JW. Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism? *Medical Journal of Australia*. 2011;195(3):139-142. Exclude: Publication type-commentary.

315. Hoagland LE, Triplett DA, Peng F, Barna L. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method. *Thromb Res*. 1996;83(5):363-373. Exclude: Date.

316. Hoh BL, Gong Y, McDonough CW, et al. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial

atherosclerotic disease. *Journal of Neurosurgery*. 2016;124(6):1746-1751. Exclude: Not intervention of interest.

317. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 Suppl):e152S-184S. Exclude: Publication type-not systematic review.

318. Holzgreve H. [Hereditary hyperferritinemia cataract syndrome]. *Deutsche Medizinische Wochenschrift*. 2011;136(38):1895-1898. Exclude: Not English.

319. Horne BD, Lenzini PA, Wadelius M, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. *Thromb Haemost*. 2012;107(2):232-240. Exclude: Publication type-not randomized control trial.

320. Huang SW, Xiang DK, Wu HL, Chen BL, An BQ, Li GF. [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose]. *Chung-Hua i Hsueh i Chuan Hsueh Tsa Chih*. 2011;28(6):661-665. Exclude: Not English.

321. Huang TS, Zhang L, He Q, et al. DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation. *Australasian Physical & Engineering Sciences in Medicine*. 2017;40(1):249-258. Exclude: Publication type-not systematic review.

322. Hughes DA, Pirmohamed M. Warfarin pharmacogenetics: economic considerations. *Pharmacoeconomics*. 2007;25(11):899-902. Exclude: Publication type-commentary.

323. Humphries SE, Hingorani A. Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease. *Vascular Pharmacology*. 2006;44(2):119-125. Exclude: Date.

324. Huntington JA, Gettins PG. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin. *Biochemistry*. 1998;37(10):3272-3277. Exclude: Date.

325. Hynicka LM, Cahoon WD, Jr., Bukaveckas BL. Genetic testing for warfarin therapy initiation. *Annals of Pharmacotherapy*. 2008;42(9):1298-1303. Exclude: Publication type-not systematic review.

326. Ichihara N, Ishigami T, Umemura S. Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. *Journal of Cardiology*. 2015;65(3):178-184. Exclude: Publication type-not randomized control trial.

327. Ieiri I, Fukae M, Maeda K, et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. *International Journal of Clinical Pharmacology & Therapeutics*. 2012;50(10):689-700. Exclude: Publication type-not randomized control trial.

328. International Warfarin Pharmacogenetics C, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data.[Erratum appears in N Engl J Med. 2009

Oct 15;361(16):1613 Note: Dosage error in article text]. *New England Journal of Medicine*. 2009;360(8):753-764. Exclude: Publication type-not randomized control trial.

329. Isaza C, Beltran L, Henao J, et al. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients]. *Biomedica*. 2010;30(3):410-420. Exclude: Not English.

330. Issac MS, El-Nahid MS, Wissa MY. Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population. *Molecular Diagnosis & Therapy*. 2014;18(1):73-83. Exclude: Publication type-not randomized control trial.

331. Iwao Y, Anraku M, Yamasaki K, et al. Oxidation of Arg-410 promotes the elimination of human serum albumin. *Biochimica et Biophysica Acta*. 2006;1764(4):743-749. Exclude: Date.

332. Iwuchukwu OF, Ramirez AH, Shi Y, et al. Genetic determinants of variability in warfarin response after the dose-titration phase. *Pharmacogenetics and Genomics*. 2016;26(11):510-516. Exclude: Publication type-not randomized control trial.

333. Izaguirre G, Aguila S, Qi L, et al. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease. *Journal of Biological Chemistry*. 2014;289(49):34049-34064. Exclude: Publication type-not randomized control trial.

334. Izaguirre G, Olson ST. Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa. *Journal of Biological Chemistry*. 2006;281(19):13424-13432. Exclude: Date.

335. Jagannath VA, Thaker V, Chang AB, Price AI. Vitamin K supplementation for cystic fibrosis. *Cochrane Database of Systematic Reviews*. 2017(8). Exclude: Not intervention of interest.

336. James RH, O'Dell MW. Resistance to activated protein C as an etiology for stroke in a young adult: a case report. *Archives of Physical Medicine & Rehabilitation*. 1999;80(3):343-345. Exclude: Date.

337. Jarrar YB, Lee SJ. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy. *Drug Metabolism & Drug Interactions*. 2014;29(4):211-220. Exclude: Publication type-commentary.

338. Jeong E, Lee KE, Jeong H, Chang BC, Gwak HS. Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. *Pharmacogenomics Journal*. 2015;15(1):33-37. Exclude: Publication type-not randomized control trial.

339. Jimenez-Varo E, Canadas-Garre M, Henriques CI, Pinheiro AM, Gutierrez-Pimentel MJ, Calleja-Hernandez MA. Pharmacogenetics role in the safety of acenocoumarol therapy. *Thromb Haemost*. 2014;112(3):522-536. Exclude: Publication type-commentary.

340. Jin L, Pandey P, Babine RE, et al. Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. *Journal of Biological Chemistry*. 2005;280(6):4704-4712. Exclude: Date.

341. Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N, Goldhaber SZ. Warfarin dosing and cytochrome P450 2C9 polymorphisms. *Thromb Haemost*. 2004;91(6):1123-1128. Exclude: Publication type-not randomized control trial.

342. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology--with emphasis on cytochrome p450. *Toxicological Sciences*. 2011;120(1):1-13. Exclude: Publication type-commentary.

343. Johnson EG, Horne BD, Carlquist JF, Anderson JL. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations. *Molecular Diagnosis & Therapy*. 2011;15(5):255-264. Exclude: Publication type-commentary.

344. Johnson JA. Warfarin: an old drug but still interesting. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2008;28(9):1081-1083. Exclude: Publication type-commentary.

345. Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. *Circulation*. 2012;125(16):1964-1966. Exclude: Publication type-commentary.

346. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. *Clinical Pharmacology & Therapeutics*. 2017;102(3):397-404. Exclude: Publication type-not systematic review.

347. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease--implications for personalized medicine. *Pharmacological Reviews*. 2013;65(3):987-1009. Exclude: Publication type-commentary.

348. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. *Trends in Cardiovascular Medicine*. 2015;25(1):33-41. Exclude: Publication type-commentary.

349. Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. *Clinical Pharmacology & Therapeutics*. 2011;90(4):519-531. Exclude: Publication type-commentary.

350. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. *Clinical Pharmacology & Therapeutics*. 2011;90(4):625-629. Exclude: Publication type-not systematic review.

351. Johnson JA, Klein TE, Relling MV. Clinical implementation of pharmacogenetics: more than one gene at a time. *Clinical Pharmacology & Therapeutics*. 2013;93(5):384-385. Exclude: Publication type-commentary.

352. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. *Trends in Pharmacological Sciences*. 2009;30(7):375-386. Exclude: Publication type-commentary.

353. Jonas DE, Wines R. Pharmacogenomic testing and the prospect of individualized treatment. *North Carolina Medical Journal*. 2013;74(6):485-493. Exclude: Publication type-commentary.

354. Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JH. Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. *Clinical Trials*. 2010;7(5):597-604. Exclude: No outcome of interest.

355. Jorgensen AL, Hughes DA, Hanson A, et al. Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. *Pharmacogenomics*. 2013;14(2):151-163. Exclude: Publication type-not randomized control trial.

356. Jurcut R, Florian A, Deleanu D, et al. Atherothrombosis in 2 vascular territories in a young woman: importance of thrombophilia testing. *Clinical & Applied Thrombosis/Hemostasis*. 2011;17(1):108-113. Exclude: Publication type-case report.

357. Kabagambe EK, Beasley TM, Limdi NA. Vitamin K intake, body mass index and warfarin maintenance dose. *Cardiology*. 2013;126(4):214-218. Exclude: Publication type-not randomized control trial.

358. Kadafour M, Haugh R, Posin M, Kayser SR, Shin J. Survey on warfarin pharmacogenetic testing among anticoagulation providers. *Pharmacogenomics*. 2009;10(11):1853-1860. Exclude: Publication type-not randomized control trial.

359. Kadian-Dodov DL, van der Zee SA, Scott SA, et al. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. *Vascular Medicine*. 2013;18(5):290-297. Exclude: Not intervention of interest.

360. Kahn J. The troubling persistence of race in pharmacogenomics. *Journal of Law, Medicine & Ethics*. 2012;40(4):873-885. Exclude: Publication type-not randomized control trial.

361. Kalotychou V, Tzanetea R, Konstantopoulos K, Papassotiriou I, Rombos I. Erythrocytosis due to a combination of the high oxygen affinity hemoglobin variant, Hb Olympia [beta20(B2)Val-->Met] with beta- and alpha-thalassemia mutations: first case in the literature. *Hemoglobin*. 2010;34(4):383-388. Exclude: Publication type-case report.

362. Kamal El-Din MA, Farhan MS, El Shiha RI, El-Kaffas RM, Mousa SM. Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients. *Paediatric Drugs*. 2014;16(4):337-341. Exclude: Publication type-not randomized control trial.

363. Kamal Z, Nordstad MG, Molden E. [A 60-year-old man with heart failure, dry cough and elevated INR values]. *Tidsskrift for Den Norske Laegeforening*. 2008;128(15):1677-1679. Exclude: Not English.

364. Kamali F. Genetic influences on the response to warfarin. *Current Opinion in Hematology*. 2006;13(5):357-361. Exclude: Date.

365. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. *Clinical Pharmacology & Therapeutics*. 2004;75(3):204-212. Exclude: Not intervention of interest.

366. Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. *British Journal of Clinical Pharmacology*. 2006;61(6):746-751. Exclude: Date.

367. Kamali F, Wynne H. Pharmacogenetics of warfarin. *Annual Review of Medicine*. 2010;61:63-75. Exclude: Publication type-commentary.

368. Kamali X, Wulasihan M, Yang YC, Lu WH, Liu ZQ, He PY. Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. *Lipids in Health & Disease*. 2013;12:149. Exclude: Publication type-not randomized control trial.

369. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. *Journal of General Internal Medicine*. 2009;24(5):656-664. Exclude: Not most recent systematic review.

370. Karaca S, Bozkurt NC, Cesuroglu T, et al. International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. *Pharmacogenomics*. 2015;16(10):1109-1118. Exclude: Publication type-not randomized control trial.

371. Karch SB. Changing times: DNA resequencing and the "nearly normal autopsy". *Journal of Forensic & Legal Medicine*. 2007;14(7):389-397. Exclude: Publication type-commentary.

372. Karnik ND, Sridharan K, Tiwari D, Gupta V. CYP2C9 3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin. *Indian Journal of Pharmacology*. 2014;46(5):549-550. Exclude: Publication type-case report.

373. Kasner SE, Wang L, French B, et al. Warfarin dosing algorithms and the need for human intervention. *American Journal of Medicine*. 2016;129(4):431-437. Exclude: No outcome of interest.

374. Kasner SE, Wang L, French B, et al. The impact of inpatient versus outpatient initiation on early warfarin dosing. *American Journal of Cardiovascular Drugs*. 2015;15(4):267-274. Exclude: No outcome of interest.

375. Kaufman AL, Spitz J, Jacobs M, et al. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. *Mayo Clinic Proceedings*. 2015;90(6):716-729. Exclude: Publication type-not randomized control trial.

376. Kawai VK, Cunningham A, Vear SI, et al. Genotype and risk of major bleeding during warfarin treatment. *Pharmacogenomics*. 2014;15(16):1973-1983. Exclude: Publication type-not randomized control trial.

377. Kawamoto K, Orlando LA, Voora D, et al. Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays. *AMIA Annual Symposium Proceedings/AMIA Symposium*. 2009;2009:307-311. Exclude: Not intervention of interest.

378. Kazi DS, Hlatky MA. The value of pharmacogenetic testing-reply. *JAMA Internal Medicine*. 2015;175(2):314-315. Exclude: Publication type-letter.

379. Keppler-Noreuil KM, Wenzel TJ. Binder phenotype: associated findings and etiologic mechanisms. *Journal of Craniofacial Surgery*. 2010;21(5):1339-1345. Exclude: Publication type-case report.

380. Kessler P. [Pharmacogenetics of warfarin]. *Vnitrni Lekarstvi*. 2006;52 Suppl 1:31-34. Exclude: Date.

381. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. *Pharmacogenetics*. 2001;11(9):803-808. Exclude: Date.

382. Kiechle FL, Zhang X, Holland-Staley CA. The -omics era and its impact. *Archives of Pathology & Laboratory Medicine*. 2004;128(12):1337-1345. Exclude: Not intervention of interest.

383. Kim JH, Schwinn DA, Landau R. Pharmacogenomics and perioperative medicine--implications for modern clinical practice. *Canadian Journal of Anaesthesia*. 2008;55(12):799-806. Exclude: Publication type-commentary.

384. Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. *Journal of Clinical Pharmacology*. 2009;49(2):138-146. Exclude: Publication type-commentary.

385. Kim MJ, Nafziger AN, Kashuba AD, et al. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. *European Journal of Clinical Pharmacology*. 2006;62(6):431-436. Exclude: Not intervention of interest.

386. Kim SY, Kang JY, Hartman JH, et al. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. *Drug Metabolism Letters*. 2012;6(3):157-164. Exclude: Publication type-not randomized control trial.

387. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. *American Journal of Health-System Pharmacy*. 2007;64(2):166-175. Exclude: Publication type-not randomized control trial.

388. Kimmel SE. Warfarin pharmacogenomics: current best evidence. *J Thromb Haemost*. 2015;13 Suppl 1:S266-271. Exclude: Publication type-commentary.

389. Kimmel SE, French B, Kasner SE, et al. The clarification of optimal anticoagulation through genetics (COAG) trial. *Circulation*. 2013;128(24):2711. Exclude: Publication type-conference abstract.

390. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. *Thromb Res*. 2007;120(2):181-186. Exclude: Publication type-not randomized control trial.

391. King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. *Pharmacogenetics*. 2004;14(12):813-822. Exclude: Date.

392. King CR, Porche-Sorbet RM, Gage BF, et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. *American Journal of Clinical Pathology*. 2008;129(6):876-883. Exclude: Not intervention of interest.

393. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. *Clinical Pharmacology & Therapeutics*. 2005;77(1):1-16. Exclude: Date.

394. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. *Biochimica et Biophysica Acta*. 2007;1770(3):489-494. Exclude: Publication type-commentary.

395. Kirchhof P, Breithardt G, Aliot E, et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. *Europace*. 2013;15(11):1540-1556. Exclude: Publication type-commentary.

396. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. *Cleveland Clinic Journal of Medicine*. 2011;78(4):243-257. Exclude: Publication type-commentary.

397. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. *Clinical Pharmacokinetics*. 2011;50(5):281-294. Exclude: Publication type-not systematic review.

398. Knight JC. Genetics and the general physician: insights, applications and future challenges. *Qjm*. 2009;102(11):757-772. Exclude: Publication type-commentary.

399. Kokh NV, Slepukhina AA, Tsvetovskaya GA, Lifshits GA. [Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy]. *Kardiologiia*. 2015;55(4):57-60. Exclude: Not English.

400. Konstantinides S, Lankeit M. Pulmonary embolism hotline 2012. Recent and expected trials. *Hamostaseologie*. 2013;33(1):43-50. Exclude: Not intervention of interest.

401. Konstantinides S, Torbicki A. Management of venous thrombo-embolism: an update. *European Heart Journal*. 2014;35(41):2855-2863. Exclude: Publication type-commentary.

402. Koren G. Personalized Medicine-Disregarding the Obvious: Analysis of Trends Among Articles Published on "Personalized Medicine". *Therapeutic Drug Monitoring*. 2015;37(5):559. Exclude: Publication type-commentary.

403. Korneva E, Ratchina S, Miljagin V, Kozhuhova L, Romanov A, Eidelshtein M. Evaluation of pharmacogenetic-based warfarin therapy in patients with atrial fibrillation in smolensk region of Russia: Results. *Basic & Clinical Pharmacology & Toxicology*. 2011;109:27-28. Exclude: Publication type-conference abstract.

404. Kosaki K, Yamaghishi C, Sato R, et al. 1173C>T polymorphism in VKORC1 modulates the required warfarin dose. *Pediatric Cardiology*. 2006;27(6):685-688. Exclude: Date.

405. Kovac M, Rakicevic L, Maslac A, Radojkovic D. [The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use]. *Vojnosanitetski Pregled*. 2009;66(8):617-621. Exclude: Not English.

406. Kovac MK, Maslac AR, Rakicevic LB, Radojkovic DP. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. *Blood Coagulation & Fibrinolysis*. 2010;21(6):558-563. Exclude: Publication type-not randomized control trial.

407. Kovac MK, Rakicevic LB, Kusic-Tisma JS, Radojkovic DP. Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation. *J Thromb Thrombolys*. 2013;35(1):90-94. Exclude: Publication type-not randomized control trial.

408. Kovac MK, Rakicevic LB, Radojkovic DP. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9 1/ 3 genotypes. *J Thromb Thrombolys*. 2011;32(3):368-371. Exclude: Publication type-case report.

409. Kozek-Langenecker SA. Perioperative management issues of direct oral anticoagulants. *Seminars in Hematology*. 2014;51(2):112-120. Exclude: Publication type-commentary.

410. Kragh-Hansen U, Brennan SO, Galliano M, Sugita O. Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations. *Molecular Pharmacology*. 1990;37(2):238-242. Exclude: Date.

411. Krajciova L, Deziova L, Petrovic R, Luha J, Turcani P, Chandoga J. Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice. *Bratislavske Lekarske Listy*. 2014;115(9):563-568. Exclude: Publication type-not randomized control trial.

412. Krajciova L, Petrovic R, Deziova L, Chandoga J, Turcani P. Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population. *European Journal of Haematology*. 2014;93(4):320-328. Exclude: Publication type-not randomized control trial.

413. Kringen MK, Haug KB, Grimholt RM, et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. *Journal of Biomedicine & Biotechnology*. 2011;2011:739751. Exclude: Publication type-not randomized control trial.

414. Krishna Kumar D, Shewade DG, Loriot MA, et al. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. *European Journal of Clinical Pharmacology*. 2014;70(1):47-56. Exclude: Publication type-not randomized control trial.

415. Kroh HK, Panizzi P, Tchaikovski S, et al. Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo. *Journal of Biological Chemistry*. 2011;286(26):23345-23356. Exclude: Publication type-not randomized control trial.

416. Krynetskiy E, McDonnell P. Building individualized medicine: prevention of adverse reactions to warfarin therapy. *Journal of Pharmacology & Experimental Therapeutics*. 2007;322(2):427-434. Exclude: Publication type-not randomized control trial.

417. Kuanprasert S, Dettrairat S, Palacajornsuk P, Kunachiwa W, Phrommintikul A. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. *Journal of the Medical Association of Thailand.* 2009;92(12):1597-1601. Exclude: Publication type-not randomized control trial.

418. Kudzi W, Ahorhorlu SY, Dzudzor B, Olayemi E, Nartey ET, Asmah RH. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. *BMC Research Notes.* 2016;9(1):507. Exclude: Publication type-not randomized control trial.

419. Kulkarni V, Bhave A, Munshi RK, et al. Warfarin therapy--why one dose does not fit all! *Journal of the Association of Physicians of India.* 2013;61(8):571-573. Exclude: Publication type-case report.

420. Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ. Minimizing the Risk of Bleeding with NOACs in the Elderly. *Drugs & Aging.* 2016;33(7):491-500. Exclude: Publication type-commentary.

421. Kurnik D, Loebstein R, Halkin H, Gak E, Almog S. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. *Pharmacogenomics.* 2009;10(12):1955-1965. Exclude: Publication type-not systematic review.

422. Kurnik D, Qasim H, Sominsky S, et al. Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. *Thromb Haemost.* 2012;108(4):781-788. Exclude: No outcome of interest.

423. Kusama M, Maeda K, Chiba K, Aoyama A, Sugiyama Y. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. *Pharmaceutical Research.* 2009;26(4):822-835. Exclude: Publication type-not randomized control trial.

424. Kwon A, Jo SH, Im HJ, et al. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy. *J Thromb Thrombolys.* 2011;32(4):467-473. Exclude: Not intervention of interest.

425. Kwon MJ, On YK, Huh W, et al. Low dose requirement for warfarin treatment in a patient with CYP2C9 3/ 13 genotype. *Clinica Chimica Acta.* 2011;412(23-24):2343-2345. Exclude: Publication type-case report.

426. Lackner TE. Pharmacogenomic dosing of warfarin: ready or not? *Consultant Pharmacist.* 2008;23(8):614-619. Exclude: Publication type-commentary.

427. Lacut K, Ayme-Dietrich E, Gourhant L, et al. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. *British Journal of Clinical Pharmacology.* 2012;73(3):428-436. Exclude: Publication type-not randomized control trial.

428. Lagishetty CV, Deng J, Lesko LJ, Rogers H, Pacanowski M, Schmidt S. How Informative Are Drug-Drug Interactions of Gene-Drug Interactions? *Journal of Clinical Pharmacology.* 2016;56(10):1221-1231. Exclude: Publication type-commentary.

429. Laine K, Lundgren S, Ketonen M. [Genetic mutation as a risk factor for a patient treated with warfarin]. *Duodecim.* 2005;121(2):177-180. Exclude: Not English.

430. Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. *Clinical Pharmacokinetics*. 2006;45(12):1189-1200. Exclude: Date.

431. Lal S, Sandanaraj E, Jada SR, et al. Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. *British Journal of Clinical Pharmacology*. 2008;65(2):260-264. Exclude: Not intervention of interest.

432. Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese. *British Journal of Clinical Pharmacology*. 2012;73(3):340-347. Exclude: Publication type-commentary.

433. Lamoureux F, Duflot T, French Network of P. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). *Therapie*. 2017;72(2):257-267. Exclude: Publication type-not systematic review.

434. Lanfear DE, McLeod HL. Pharmacogenetics: using DNA to optimize drug therapy. *American Family Physician*. 2007;76(8):1179-1182. Exclude: Publication type-commentary.

435. Langdown J, Johnson DJ, Baglin TP, Huntington JA. Allosteric activation of antithrombin critically depends upon hinge region extension. *Journal of Biological Chemistry*. 2004;279(45):47288-47297. Exclude: Date.

436. Langer E, Ziemer S. [Established anticoagulants in secondary haemostasis--Vitamin K antagonists, heparins]. *Hamostaseologie*. 2009;29(3):241-246. Exclude: Not English.

437. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. *Journal of Molecular Diagnostics*. 2009;11(3):216-225. Exclude: Not intervention of interest.

438. Lazo-Langner A, Kovacs MJ. Predicting warfarin dose. *Current Opinion in Pulmonary Medicine*. 2010;16(5):426-431. Exclude: Publication type-commentary.

439. Lazo-Langner A, Monkman K, Kovacs MJ. Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram. *J Thromb Haemost*. 2009;7(8):1276-1283. Exclude: Publication type-not randomized control trial.

440. Le Cam-Duchez V, Fretigny M, Cailleux N, Gandelin C, Levesque H, Borg JY. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets. *Thromb Res*. 2010;126(3):e235-237. Exclude: Publication type-letter.

441. Lee CR. Warfarin initiation and the potential role of genomic-guided dosing. *Clinical Medicine & Research*. 2005;3(4):205-206. Exclude: Date.

442. Lee JE, Ryu DH, Jeong HJ, et al. Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9 1/ 3 and thyrotoxicosis. *Journal of Korean Medical Science*. 2014;29(9):1317-1319. Exclude: Publication type-case report.

443. Lee JW, Aminkeng F, Bhavsar AP, et al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. *Clinical Genetics*. 2014;86(1):21-28. Exclude: Publication type-commentary.

444. Lee KC, Ma JD, Kuo GM. Pharmacogenomics: bridging the gap between science and practice. *Journal of the American Pharmacists Association: JAPhA*. 2010;50(1):e1-14; quiz e15-17. Exclude: Not intervention of interest.

445. Lee KE, Chang BC, Kim HO, et al. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. *Therapeutic Drug Monitoring*. 2012;34(3):275-282. Exclude: Publication type-not randomized control trial.

446. Lee MT, Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. *Pharmacogenomics*. 2009;10(12):1905-1913. Exclude: Publication type-not randomized control trial.

447. Lee MT, Chen CH, Chuang HP, et al. VKORC1 haplotypes in five East-Asian populations and Indians. *Pharmacogenomics*. 2009;10(10):1609-1616. Exclude: Publication type-not randomized control trial.

448. Lee MT, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. *Journal of Human Genetics*. 2013;58(6):334-338. Exclude: Publication type-commentary.

449. Lee SC. Refining the use of warfarin through genetic testing. *International Angiology*. 2008;27(4):271-273. Exclude: Publication type-commentary.

450. Lee SY, Kim JS, Kim JW. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9. *Yonsei Medical Journal*. 2005;46(6):843-846. Exclude: Date.

451. Lee SY, Nam MH, Kim JS, Kim JW. A case report of a patient carrying CYP2C9 3/4 genotype with extremely low warfarin dose requirement. *Journal of Korean Medical Science*. 2007;22(3):557-559. Exclude: Publication type-case report.

452. Lee YM, Eggen J, Soni V, Drozda K, Nutescu EA, Cavallari LH. Warfarin dose requirements in a patient with the CYP2C9 14 allele. *Pharmacogenomics*. 2014;15(7):909-914. Exclude: Publication type-case report.

453. Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. *American Journal of Geriatric Pharmacotherapy*. 2009;7(4):197-203. Exclude: No outcome of interest.

454. Lefevre F, Goodman SN, Piper MA. Pharmacogenetic testing for warfarin dosing still awaits validation. *Journal of the American College of Cardiology*. 2011;57(6):756; author reply 756-757. Exclude: Publication type-letter.

455. Lei X, Guo Y, Sun J, et al. Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients. *American Journal of Hematology*. 2012;87(5):541-544. Exclude: Not intervention of interest.

456. Lentz SR. Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants. *Clinical Pharmacology & Therapeutics*. 2016;100(2):128-130. Exclude: Publication type-commentary.

457. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. *Clinical Pharmacology & Therapeutics*. 2010;87(5):572-578. Exclude: Not intervention of interest.

458. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. *J Thromb Haemost*. 2008;6(10):1655-1662. Exclude: Not intervention of interest.

459. Lesko LJ. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. *Clinical Pharmacology & Therapeutics*. 2008;84(3):301-303. Exclude: Publication type-commentary.

460. Levigne S, Thiec F, Cherel G, Irving JA, Fribourg C, Christophe OD. Role of the alpha-helix 163-170 in factor Xa catalytic activity. *Journal of Biological Chemistry*. 2007;282(43):31569-31579. Exclude: Not intervention of interest.

461. Li J, Liu S, Yang JH, et al. [A randomized controlled study of the VKORC1 and CYP2C9 genotypes in guiding warfarin therapy for pulmonary thromboembolism]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2013;36(12):950-953. Exclude: Not English.

462. Li S, Zou Y, Wang X, et al. Warfarin dosage response related pharmacogenetics in Chinese population. *PLoS ONE [Electronic Resource]*. 2015;10(1):e0116463. Exclude: Not intervention of interest.

463. Li T, Lange LA, Li X, et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. *Journal of Medical Genetics*. 2006;43(9):740-744. Exclude: Date.

464. Li X, Liu R, Luo ZY, et al. Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. *Pharmacogenomics*. 2015;16(6):583-590. Exclude: Not intervention of interest.

465. Li X, Liu R, Yan H, et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. *Journal of Clinical Pharmacology*. 2015;55(3):251-257. Exclude: Not intervention of interest.

466. Li X, Yang J, Wang X, Xu Q, Zhang Y, Yin T. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. *Thromb Res*. 2015;135(4):621-629. Exclude: Individual studies from systematic review are included.

467. Li Y, Jortani SA, Ramey-Hartung B, Hudson E, Lemieux B, Kong H. Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays. *Clinica Chimica Acta*. 2011;412(1-2):79-85. Exclude: Publication type-not randomized control trial.

468. Liang R, Li L, Li C, et al. Impact of CYP2C9 3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. *J Thromb Thrombolys.* 2012;34(1):120-125. Exclude: Not intervention of interest.

469. Liao Z, Feng S, Ling P, Zhang G. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. *J Thromb Thrombolys.* 2015;39(2):228-234. Exclude: Individual studies from systematic review are included.

470. Liboredo R, Pena SD. Pharmacogenomics: accessing important alleles by imputation from commercial genome-wide SNP arrays. *Genetics & Molecular Research.* 2014;13(3):5713-5721. Exclude: Publication type-not randomized control trial.

471. Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. *Expert Opinion on Drug Safety.* 2010;9(2):215-223. Exclude: Not intervention of interest.

472. Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. *Blood Cells Molecules & Diseases.* 2006;37(2):100-106. Exclude: Not intervention of interest.

473. Limdi NA, Brown TM, Yan Q, et al. Race influences warfarin dose changes associated with genetic factors. *Blood.* 2015;126(4):539-545. Exclude: Publication type-not randomized control trial.

474. Limdi NA, Nolin TD, Booth SL, et al. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. *American Journal of Kidney Diseases.* 2015;65(5):701-709. Exclude: Publication type-not randomized control trial.

475. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy.* 2008;28(9):1084-1097. Exclude: Publication type-commentary.

476. Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. *Journal of Clinical Epidemiology.* 2010;63(9):960-969. Exclude: Publication type-commentary.

477. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. *Blood.* 2010;115(18):3827-3834. Exclude: Publication type-not randomized control trial.

478. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. *Blood Cells Molecules & Diseases.* 2009;43(1):119-128. Exclude: Publication type-not randomized control trial.

479. Lin M, Yu L, Qiu H, Wang Q, Zhang J, Song H. Verification of five pharmacogenomics-based warfarin administration models. *Indian Journal of Pharmacology.* 2016;48(3):258-263. Exclude: Publication type-not randomized control trial.

480. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin. *Clinica Chimica Acta.* 2001;308(1-2):9-15. Exclude: Date.

481. Linder MW, Bon Homme M, Reynolds KK, et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. *Clinical Chemistry*. 2009;55(10):1861-1868. Exclude: Publication type-not randomized control trial.

482. Linder MW, Valdes R, Jr. Genetic mechanisms for variability in drug response and toxicity. *Journal of Analytical Toxicology*. 2001;25(5):405-413. Exclude: Date.

483. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. *European Journal of Clinical Pharmacology*. 2009;65(4):365-375. Exclude: Not intervention of interest.

484. Lindh JD, Kublickas M, Westgren M, Rane A. Internet based clinical trial protocols -- as applied to a study of warfarin pharmacogenetics. *British Journal of Clinical Pharmacology*. 2004;58(5):482-487. Exclude: Date.

485. Lip GY, Potpara T, Boriani G, Blomstrom-Lundqvist C. A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. *Journal of Internal Medicine*. 2016;279(5):467-476. Exclude: Publication type-commentary.

486. Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? *Clinical Chemistry & Laboratory Medicine*. 2009;47(5):503-515. Exclude: Publication type-commentary.

487. Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. *Seminars in Thrombosis & Hemostasis*. 2007;33(8):759-770. Exclude: Publication type-commentary.

488. Liu J, Jiang HH, Wu DK, et al. Effect of gene polymorphims on the warfarin treatment at initial stage. *Pharmacogenomics Journal*. 2017;17(1):47-52. Exclude: Publication type-not randomized control trial.

489. Liu R, Li X, Zhang W, Zhou HH. Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database. *PLoS ONE [Electronic Resource]*. 2015;10(8):e0135784. Exclude: Not intervention of interest.

490. Liu Y, Jeong H, Takahashi H, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (8) polymorphism. *Clinical Pharmacology & Therapeutics*. 2012;91(4):660-665. Exclude: Not intervention of interest.

491. Liu Y, Yang J, Xu Q, et al. Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. *Thromb Res*. 2012;130(3):435-440. Exclude: Not intervention of interest.

492. Liu YP, Gu YM, Thijs L, et al. Inactive matrix Gla protein is causally related to adverse health outcomes: a Mendelian randomization study in a Flemish population. *Hypertension*. 2015;65(2):463-470. Exclude: Not intervention of interest.

493. Loh M, Soong R. Challenges and pitfalls in the introduction of pharmacogenetics for cancer. *Annals of the Academy of Medicine, Singapore.* 2011;40(8):369-374. Exclude: Publication type-commentary.

494. Lopez I, Sanguesa E, Vancraenendonck Y, Zuriaga E, Ribate MP, Garcia CB. Can pharmacogenetics help patients under chronic treatment with coumarin anticoagulants? *Drug Metabolism and Personalized Therapy.* 2016;31(4):191-196. Exclude: Publication type-commentary.

495. Loriot MA, Beaune P. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety]. *Revue du Praticien.* 2007;57(12):1281-1286. Exclude: Publication type-commentary.

496. Lu WJ, Miller NJ. Point-Counterpoint: Genotype-Guided Warfarin Therapy. *South Dakota Medicine: The Journal of the South Dakota State Medical Association.* 2017;70(2):54-56. Exclude: Publication type-commentary.

497. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. *J Thromb Haemost.* 2010;8(5):1018-1026. Exclude: Not intervention of interest.

498. Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. *British Journal of Clinical Pharmacology.* 2010;70(2):164-170. Exclude: Publication type-commentary.

499. Luxembourg B, Schneider K, Sittinger K, et al. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. *Thromb Haemost.* 2011;105(1):169-180. Exclude: Publication type-not randomized control trial.

500. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. *American Family Physician.* 2007;76(3):391-396. Exclude: Publication type-commentary.

501. Lyon E, McMillin G, Melis R. Pharmacogenetic testing for warfarin sensitivity. *Clinics in Laboratory Medicine.* 2008;28(4):525-537. Exclude: Publication type-commentary.

502. Ma C, Zhang Y, Xu Q, et al. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. *International Journal of Hematology.* 2012;96(6):719-728. Exclude: Publication type-not randomized control trial.

503. Maagdenberg H, Vijverberg SJ, Bierings MB, et al. Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. *Paediatric Drugs.* 2016;18(4):251-260. Exclude: Publication type-commentary.

504. MacKenzie M, Hall R. Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. *Canadian Journal of Anaesthesia.* 2017;64(1):45-64. Exclude: Publication type-not systematic review.

505. Mahajan P, Meyer KS, Wall GC, Price HJ. Clinical applications of pharmacogenomics guided warfarin dosing. *International Journal of Clinical Pharmacy*. 2011;33(1):10-19. Exclude: Not most recent systematic review.

506. Mahajan P, Meyer KS, Wall GC, Price HJ. Clinical applications of pharmacogenomics guided warfarin dosing. *International Journal of Clinical Pharmacy*. 2013;35(3):359-368. Exclude: Not most recent systematic review.

507. Mahtani KR, Heneghan CJ, Nunan D, et al. Optimal loading dose of warfarin for the initiation of oral anticoagulation. *Cochrane Database of Systematic Reviews*. 2012(12). Exclude: Not most recent systematic review.

508. Maier CL, Duncan A, Hill CE. Pharmacogenetics in Oral Antithrombotic Therapy. *Clinics in Laboratory Medicine*. 2016;36(3):461-472. Exclude: Publication type-commentary.

509. Maluso A. Pharmacogenomic Testing and Warfarin Management. *Oncology Nursing Forum*. 2015;42(5):563-565. Exclude: Publication type-commentary.

510. Mandic D, Bozina N, Mandic S, Samardzija M, Milostic-Srb A, Rumora L. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. *International Journal of Clinical Pharmacology & Therapeutics*. 2015;53(11):905-913. Exclude: Publication type-not randomized control trial.

511. Mannucci PM, Spreafico M, Peyvandi F. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. *J Thromb Haemost*. 2008;6(9):1450-1452. Exclude: Publication type-commentary.

512. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. *Pharmacogenomics*. 2010;11(4):493-496. Exclude: Not intervention of interest.

513. Marcatto LR, Sacilotto L, Bueno CT, et al. Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. *BMC Cardiovascular Disorders*. 2016;16(1):224. Exclude: No outcome of interest.

514. Marin-Leblanc M, Perreault S, Bahroun I, et al. Validation of warfarin pharmacogenetic algorithms in clinical practice. *Pharmacogenomics*. 2012;13(1):21-29. Exclude: Publication type-not randomized control trial.

515. Mark L, Marki-Zay J, Fodor L, Kondacs A, Paragh G, Katona A. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol]. *Orvosi Hetilap*. 2005;146(16):739-743. Exclude: Date.

516. Markus HS. Stroke genetics: prospects for personalized medicine. *BMC Medicine*. 2012;10:113. Exclude: Publication type-commentary.

517. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. *J Thromb Haemost*. 2006;4(2):473-474. Exclude: Date.

518. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor pathway inhibitor binds to platelet thrombospondin-1. *Journal of Biological Chemistry*. 2000;275(41):31715-31721. Exclude: Date.

519. Masuda Y, Matsuno K, Shimizu C. [Companion Diagnostics for Thrombotic Disease]. *Rinsho Byori - Japanese Journal of Clinical Pathology*. 2015;63(11):1316-1322. Exclude: Not English.

520. Mazur-Bialy AI, Zdebska K, Wypasek E, Undas A. Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1 2A and the CYP2C9 3/ 3 alleles: genetic testing to support switching to new oral anticoagulants. *Thromb Res*. 2013;131(3):279-280. Exclude: Publication type-letter.

521. Mazzaccara C, Conti V, Liguori R, et al. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. *PLoS ONE [Electronic Resource]*. 2013;8(8):e71505. Exclude: Publication type-not randomized control trial.

522. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. *Genet Med*. 2008;10(2):89-98. Exclude: Not most recent systematic review.

523. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. *Molecular Pharmacology*. 2009;75(6):1337-1346. Exclude: Publication type-not randomized control trial.

524. McMillin GA, Melis R, Wilson A, et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. *Ther Drug Monit*. 2010;32(3):338-345. Exclude: Publication type-not randomized control trial.

525. McMillin GA, Vazquez SR, Pendleton RC. Current challenges in personalizing warfarin therapy. *Expert Review of Clinical Pharmacology*. 2011;4(3):349-362. Exclude: Publication type-commentary.

526. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. *Health Policy*. 2010;94(2):91-100. Exclude: No outcome of interest.

527. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. *Thromb Haemost*. 2008;100(2):229-239. Exclude: Publication type-not randomized control trial.

528. Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet*. 2015;385(9984):2280-2287. Exclude: Not intervention of interest.

529. Melton BL, Zillich AJ, Saleem J, Russ AL, Tisdale JE, Overholser BR. Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing. *Applied Clinical Informatics*. 2016;7(4):1088-1106. Exclude: Publication type-not randomized control trial.

530. Merali Z, Ross S, Pare G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. *Drug Metabolism & Drug Interactions*. 2014;29(3):143-151. Exclude: Publication type-commentary.

531. Meschia JF. Pharmacogenetics and stroke. *Stroke*. 2009;40(11):3641-3645. Exclude: Publication type-commentary.

532. Meschia JF, Worrall BB, Rich SS. Genetic susceptibility to ischemic stroke. *Nature Reviews Neurology*. 2011;7(7):369-378. Exclude: Publication type-commentary.

533. Mesika Y, Lee BC, Tsimerman Y, Roitman H, Park HK. Using pharmacogenetics knowledge to increase accuracy of alerts for adverse drug events. *Studies in Health Technology & Informatics*. 2011;169:569-573. Exclude: Publication type-commentary.

534. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. *European Journal of Clinical Pharmacology*. 2007;63(12):1135-1141. Exclude: Not intervention of interest.

535. Mieszczanek J, Harrison LM, Cappello M. Ancylostoma ceylanicum anticoagulant peptide-1: role of the predicted reactive site amino acid in mediating inhibition of coagulation factors Xa and VIIa. *Molecular & Biochemical Parasitology*. 2004;137(1):151-159. Exclude: Date.

536. Militaru FC, Vesa SC, Pop TR, Buzoianu AD. Pharmacogenetics aspects of oral anticoagulants therapy. *Journal of Medicine & Life*. 2015;8(2):171-175. Exclude: Publication type-not randomized control trial.

537. Misasi S, Martini G, Paoletti O, et al. VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. *Medicine*. 2016;95(52):e5451. Exclude: Publication type-not randomized control trial.

538. Mitri Z, Esmerian MO, Simaan JA, Sabra R, Zgheib NK. Pharmacogenetics and personalized medicine: the future for drug prescribing. *Journal Medical Libanais - Lebanese Medical Journal*. 2010;58(2):101-104. Exclude: Not intervention of interest.

539. Mitropoulou C, Fragoulakis V, Bozina N, et al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. *Pharmacogenomics*. 2015;16(2):137-148. Exclude: Not appropriate setting.

540. Mizzi C, Dalabira E, Kumuthini J, et al. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.[Erratum appears in PLoS One. 2017 Feb 16;12 (2):e0172595; PMID: 28207884]. *PLoS ONE [Electronic Resource]*. 2016;11(9):e0162866. Exclude: Publication type-not randomized control trial.

541. Moreau C, Loriot MA, Siguret V. [Vitamin K antagonists: from discovery to pharmacogenetics]. *Annales de Biologie Clinique*. 2012;70(5):539-551. Exclude: Not English.

542. Moreau C, Pautas E, Duverlie C, et al. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. *Thromb Haemost*. 2014;111(4):705-712. Exclude: Not intervention of interest.

543. Moreau C, Siguret V, Loriot MA. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion]. *Revue de Medecine Interne.* 2010;31(5):361-368. Exclude: Not English.

544. Morin S, Bodin L, Loriot MA, et al. Pharmacogenetics of acenocoumarol pharmacodynamics. *Clinical Pharmacology & Therapeutics.* 2004;75(5):403-414. Exclude: Date.

545. Morrison A, Levy R. Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes. *Pharmacogenomics.* 2004;5(6):673-689. Exclude: Date.

546. Morse BL, Kim RB. Is personalized medicine a dream or a reality? *Critical Reviews in Clinical Laboratory Sciences.* 2015;52(1):1-11. Exclude: Publication type-commentary.

547. Moser M, Olivier CB, Bode C. Triple antithrombotic therapy in cardiac patients: more questions than answers. *European Heart Journal.* 2014;35(4):216-223. Exclude: Publication type-commentary.

548. Mosher CM, Court MH. Comparative and veterinary pharmacogenomics. *Handbook of Experimental Pharmacology.* 2010(199):49-77. Exclude: Not intervention of interest.

549. Mousa SA. Pharmacogenomics in thrombosis. *Methods in Molecular Biology.* 2010;663:277-289. Exclude: Publication type-commentary.

550. Mundi S, Distante A, De Caterina R. [Pharmacogenetic algorithms for predicting the appropriate dose of vitamin K antagonists: are they still useful?]. *Giornale Italiano di Cardiologia.* 2014;15(10):546-560. Exclude: Publication type-commentary.

551. Mundi S, Distante A, De Caterina R. [Genetic determinants of response to vitamin K antagonists]. *Giornale Italiano di Cardiologia.* 2014;15(9):482-493. Exclude: Publication type-commentary.

552. Murata M. [Possible application of pharmacogenomics to warfarin therapy]. *Rinsho Byori - Japanese Journal of Clinical Pathology.* 2011;59(6):594-597. Exclude: Publication type-commentary.

553. Murray JM, Hellinger A, Dionne R, et al. Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience. *Pediatric Cardiology.* 2015;36(4):842-850. Exclude: Publication type-not randomized control trial.

554. Mushiroda T. [Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine]. *Rinsho Byori - Japanese Journal of Clinical Pathology.* 2013;61(5):422-427. Exclude: Publication type-commentary.

555. Mushiroda T, Giacomini KM, Kubo M. Special Section on Pharmacogenomics: recent advances and future directions. *Journal of Human Genetics.* 2013;58(6):305. Exclude: Publication type-commentary.

556. Mushiroda T, Ohnishi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. *Journal of Human Genetics*. 2006;51(3):249-253. Exclude: Date.

557. Mushunje A, Zhou A, Carrell RW, Huntington JA. Heparin-induced substrate behavior of antithrombin Cambridge II. *Blood*. 2003;102(12):4028-4034. Exclude: Date.

558. Mushunje A, Zhou A, Huntington JA, Conard J, Carrell RW. Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinity. *Thromb Haemost*. 2002;88(3):436-443. Exclude: Date.

559. Mustafa S, Pabinger I, Mannhalter C. A frequent mutation in the protein S gene results in cryptic splicing. *British Journal of Haematology*. 1997;97(3):555-557. Exclude: Date.

560. Muszkat M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. *Clinical Pharmacology & Therapeutics*. 2007;82(2):215-218. Exclude: Publication type-commentary.

561. Muszkat M, Bialer O, Blotnick S, et al. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. *Clinical Therapeutics*. 2010;32(2):347-356. Exclude: Not intervention of interest.

562. Nagai R, Ohara M, Cavallari LH, et al. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. *Pharmacogenomics*. 2015;16(3):217-225. Exclude: Publication type-not randomized control trial.

563. Nahar R, Deb R, Saxena R, Puri RD, Verma IC. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians. *Pharmacological Reports: PR*. 2013;65(1):187-194. Exclude: Publication type-not randomized control trial.

564. Nahar R, Dube D, Parakh R, et al. Implication of novel CYP2C9 57 (p.Asn204His) variant in coumarin hypersensitivity. *Thromb Res*. 2013;131(6):535-539. Exclude: Publication type-not randomized control trial.

565. Nakai K, Tsuboi J, Okabayashi H, et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. *Pharmacogenomics*. 2007;8(7):713-719. Exclude: Publication type-not randomized control trial.

566. Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. *Biochimica et Biophysica Acta*. 2003;1623(2-3):88-97. Exclude: Date.

567. Nakamura Y, Takase KI, Matsushita T, et al. Recurrent Hemorrhagic Venous Infarctions Caused by Thrombosis of a Pontine Developmental Venous Anomaly and Protein S Mutation. *Journal of Stroke & Cerebrovascular Diseases*. 2016;25(11):e216-e217. Exclude: Publication type-case report.

568. Namazi S, Azarpira N, Hendijani F, Khorshid MB, Vessal G, Mehdipour AR. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. *Clinical Therapeutics.* 2010;32(6):1050-1060. Exclude: Publication type-not randomized control trial.

569. Nastasi-Catanese JA, Padilla-Gutierrez JR, Valle Y, Ortega-Gutierrez F, Gallegos-Arreola MP, Figuera LE. Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response. *Genetics & Molecular Research.* 2013;12(4):4413-4421. Exclude: Publication type-commentary.

570. Natarajan S, Ponde CK, Rajani RM, et al. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. *Pharmacological Reports: PR.* 2013;65(5):1375-1382. Exclude: Publication type-not randomized control trial.

571. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, Morarai T, Yodting T, Piriyachananusorn N. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. *Chest.* 2011;139(5):1130-1139. Exclude: Not intervention of interest.

572. Ng PC, Zhao Q, Levy S, Strausberg RL, Venter JC. Individual genomes instead of race for personalized medicine. *Clinical Pharmacology & Therapeutics.* 2008;84(3):306-309. Exclude: Not intervention of interest.

573. Ngow H, Teh LK, Langmia IM, et al. Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study. *Xenobiotica.* 2008;38(6):641-651. Exclude: Publication type-not randomized control trial.

574. Ngow HA, Wan Khairina WM, Teh LK, et al. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. *Singapore Medical Journal.* 2009;50(5):490-493. Exclude: Not intervention of interest.

575. Ni X, Zhang W, Huang RS. Pharmacogenomics discovery and implementation in genome-wide association studies era. *Wiley interdisciplinary reviews Systems biology & medicine.* 2013;5(1):1-9. Exclude: Publication type-commentary.

576. Nicolaes GA, Bock PE, Segers K, Wildhagen KC, Dahlback B, Rosing J. Inhibition of thrombin formation by active site mutated (S360A) activated protein C. *Journal of Biological Chemistry.* 2010;285(30):22890-22900. Exclude: Publication type-not randomized control trial.

577. Nielsen PB, Lundbye-Christensen S, Larsen TB, Kristensen SR, Hejlesen OK. Monitoring of anticoagulant therapy applying a dynamic statistical model. *Computer Methods & Programs in Biomedicine.* 2013;110(3):380-388. Exclude: Publication type-not randomized control trial.

578. Niinuma Y, Saito T, Takahashi M, et al. Functional characterization of 32 CYP2C9 allelic variants. *Pharmacogenomics Journal.* 2014;14(2):107-114. Exclude: Publication type-not randomized control trial.

579. Nishi K, Ueno M, Murakami Y, et al. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. *Journal of Pharmaceutical Sciences*. 2009;98(11):4316-4326. Exclude: Publication type-not randomized control trial.

580. Njovane XW, Fasinu PS, Rosenkranz B. Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area. *Cardiovascular Journal of Africa*. 2013;24(2):19-23. Exclude: Not intervention of interest.

581. Noble S, Sui J. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs? *Thromb Res*. 2016;140 Suppl 1:S154-159. Exclude: Publication type-commentary.

582. Novelli G. Personalized genomic medicine. *Internal & Emergency Medicine*. 2010;5 Suppl 1:S81-90. Exclude: Publication type-commentary.

583. Nowak G. [New anticoagulants for secondary haemostasis--anti IIa inhibitors]. *Hamostaseologie*. 2009;29(3):256-259. Exclude: Not English.

584. Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2013;33(11):1156-1164. Exclude: Not intervention of interest.

585. Obeng AO, Kaszemacher T, Abul-Husn NS, et al. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing. *Clinical Pharmacology & Therapeutics*. 2016;100(5):427-430. Exclude: Publication type-not randomized control trial.

586. O'Brien TJ, Kidd RS, Richard CA, et al. First report of warfarin dose requirements in patients possessing the CYP2C9 12 allele. *Clinica Chimica Acta*. 2013;424:73-75. Exclude: Publication type-case report.

587. O'Connor C T, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). *Expert Opinion On Drug Metabolism & Toxicology*. 2017;13(7):725-739. Exclude: Not intervention of interest.

588. Ohashi W, Tanaka H. Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events. *Journal of Medical Systems*. 2010;34(4):701-707. Exclude: Not intervention of interest.

589. Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. *European Journal of Clinical Pharmacology*. 2009;65(11):1097-1103. Exclude: Publication type-not randomized control trial.

590. Ohta N, Miyamoto Y. [Pharmacogenomics for warfarin and health economics]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*. 2010;68 Suppl 8:275-279. Exclude: Not English.

591. Oldenburg J, Bevans CG, Fregin A, Geisen C, Muller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant

VKORC1 and CYP2C9 alleles. *Thromb Haemost.* 2007;98(3):570-578. Exclude: Publication type-commentary.

592. Oldenburg J, Seidel H, Potzsch B, Watzka M. [New insight in therapeutic anticoagulation by Coumarin derivatives]. *Hamostaseologie.* 2008;28(1-2):44-50. Exclude: Publication type-commentary.

593. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clinic Proceedings.* 2008;83(6):630-638. Exclude: Publication type-not randomized control trial.

594. Olson RE. Warfarin revisited. *New England Journal of Medicine.* 1970;283(8):435-436. Exclude: Date.

595. Olson RE. The function and metabolism of vitamin K. *Annual Review of Nutrition.* 1984;4:281-337. Exclude: Not intervention of interest.

596. Olson ST, Stephens AW, Hirs CH, Bock PE, Bjork I. Kinetic characterization of the proteinase binding defect in a reactive site variant of the serpin, antithrombin. Role of the P1' residue in transition-state stabilization of antithrombin-proteinase complex formation. *Journal of Biological Chemistry.* 1995;270(17):9717-9724. Exclude: Date.

597. Ong FS, Deignan JL, Kuo JZ, et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. *Pharmacogenomics.* 2012;13(4):465-475. Exclude: Publication type-commentary.

598. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. *New England Journal of Medicine.* 1970;282(26):1448-1451. Exclude: Date.

599. O'Reilly RA, Aggeler PM. Coumarin anticoagulant drugs: hereditary resistance in man. *Federation Proceedings.* 1965;24(6):1266-1273. Exclude: Date.

600. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. *Annals of the New York Academy of Sciences.* 1968;151(2):913-931. Exclude: Date.

601. Oscarson M. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. *Clinical Chemistry & Laboratory Medicine.* 2003;41(4):573-580. Exclude: Date.

602. Osman A, Enstrom C, Lindahl TL. Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype. *Blood Coagulation & Fibrinolysis.* 2007;18(3):293-296. Exclude: Publication type-not randomized control trial.

603. Ouellet D, Bramson C, Carvajal-Gonzalez S, et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. *British Journal of Clinical Pharmacology.* 2006;61(6):741-745. Exclude: Not intervention of interest.

604. Owen RP, Altman RB, Klein TE. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. *Human Mutation.* 2008;29(4):456-460. Exclude: Publication type-commentary.

605. Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 pharmacogenomics summary. *Pharmacogenetics and Genomics.* 2010;20(10):642-644. Exclude: Publication type-commentary.

606. Owens CD. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders. *Journal of Vascular Surgery.* 2010;52(1):205-207. Exclude: Publication type-case report.

607. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. *Omics a Journal of Integrative Biology.* 2009;13(1):43-61. Exclude: Not intervention of interest.

608. Oztaner SM, Temizel TT, Erdem SR, Ozer M. A Bayesian Estimation Framework for Pharmacogenomics Driven Warfarin Dosing: A Comparative Study. *IEEE Journal of Biomedical & Health Informatics.* 2015;19(5):1724-1733. Exclude: Not intervention of interest.

609. Pai SA, Kshirsagar N. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts. *Journal of Clinical Pharmacology.* 2016;56(10):1232-1242. Exclude: Publication type-commentary.

610. Palacio L, Falla D, Tobon I, et al. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate. *Clinical & Applied Thrombosis/Hemostasis.* 2010;16(1):83-90. Exclude: Publication type-not randomized control trial.

611. Palaniappan B. Role of antenatal care in safe motherhood. *Journal of the Indian Medical Association.* 1995;93(2):53-54, 52. Exclude: Date.

612. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. *Thromb Haemost.* 2009;102(2):268-278. Exclude: Publication type-commentary.

613. Palkimas MP, Jr., Skinner HM, Gandhi PJ, Gardner AJ. Polymorphism induced sensitivity to warfarin: a review of the literature. *J Thromb Thrombolys.* 2003;15(3):205-212. Exclude: Not intervention of interest.

614. Pan Y, Cheng R, Li Z, Zhao Y, He J. PGWD: Integrating Personal Genome for Warfarin Dosing. *Interdisciplinary Sciences: Computational Life Sciences.* 2016;8(1):23-27. Exclude: Publication type-commentary.

615. Panicco P, Dodhia VR, Fantuzzi A, Gilardi G. Enzyme-based amperometric platform to determine the polymorphic response in drug metabolism by cytochromes P450. *Analytical Chemistry.* 2011;83(6):2179-2186. Exclude: Publication type-not randomized control trial.

616. Pathare A, Al Khabori M, Alkindi S, et al. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. *Journal of Human Genetics.* 2012;57(10):665-669. Exclude: Publication type-not randomized control trial.

617. Pathare AV, Al Zadjali S, Misquith R, et al. Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population. *Human Biology*. 2012;84(1):67-77. Exclude: Publication type-not randomized control trial.

618. Patrinos GP, Innocenti F. Pharmacogenomics: paving the path to personalized medicine. *Pharmacogenomics*. 2010;11(2):141-146. Exclude: Publication type-conference abstract.

619. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. *Clinical Pharmacology & Therapeutics*. 2010;87(1):57-64. Exclude: Publication type-not randomized control trial.

620. Pavani A, Naushad SM, Kumar RM, Srinath M, Malempati AR, Kutala VK. Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. *Pharmacogenomics*. 2016;17(2):121-131. Exclude: Publication type-not randomized control trial.

621. Pavani A, Naushad SM, Lakshmitha G, et al. Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement. *Pharmacogenomics*. 2016;17(12):1315-1325. Exclude: Not intervention of interest.

622. Pavani A, Naushad SM, Mishra RC, et al. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. *Pharmacogenomics*. 2012;13(8):869-878. Exclude: Publication type-not randomized control trial.

623. Pavani A, Naushad SM, Rupasree Y, et al. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. *Pharmacogenomics Journal*. 2012;12(4):306-311. Exclude: Publication type-not randomized control trial.

624. Pavani A, Naushad SM, Uma A, Kutala VK. Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. *Pharmacogenomics*. 2014;15(8):1125-1132. Exclude: Publication type-not randomized control trial.

625. Peamkrasatam S, Sriwatanakul K, Kiyotani K, et al. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. *Drug Metabolism & Pharmacokinetics*. 2006;21(6):475-484. Exclude: Not intervention of interest.

626. Pearson-Fuhrhop KM, Cramer SC. Pharmacogenetics of neural injury recovery. *Pharmacogenomics*. 2013;14(13):1635-1643. Exclude: Publication type-commentary.

627. Pedersen AB, Husted S. [Anticoagulant therapy in 2012--individualized treatment--also for the elderly]. *Ugeskrift for Laeger*. 2012;174(18):1211. Exclude: Not English.

628. Pellagatti T, Ternelli M, Frascio D, Bettini R. Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance. *International Journal of Pharmaceutical Compound*. 2017;21(3):247-250. Exclude: Not intervention of interest.

629. Pellegrini VD. DVT prophylaxis: better living through chemistry: affirms. *Orthopedics*. 2010;33(9):642. Exclude: Not intervention of interest.

630. Pelloso M, Zambon CF, Pengo V, et al. VKORC1, CYP2C9 and CYP4F2 genetic based algorithm for warfarin dosing: Preliminary results of a prospective italian study. *Biochimica clinica*. 2012;36(6):457-458. Exclude: Publication type-conference abstract.

631. Pendleton RC. Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy. 2009. Exclude: No outcome of interest.

632. Peng Q, Huang S, Chen X, et al. Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients. *Pharmacogenomics*. 2015;16(13):1465-1474. Exclude: Publication type-not randomized control trial.

633. Percha B, Garten Y, Altman RB. Discovery and explanation of drug-drug interactions via text mining. *Pacific Symposium on Biocomputing*. 2012:410-421. Exclude: Publication type-not randomized control trial.

634. Pereira NL, Sargent DJ, Farkouh ME, Rihal CS. Genotype-based clinical trials in cardiovascular disease. *Nature Reviews Cardiology*. 2015;12(8):475-487. Exclude: Publication type-commentary.

635. Perera MA, Cavallari LH, Johnson JA. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. *Clinical Pharmacology & Therapeutics*. 2014;95(3):242-244. Exclude: Publication type-commentary.

636. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet*. 2013;382(9894):790-796. Exclude: Publication type-not randomized control trial.

637. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2008;28(6):755-768. Exclude: Publication type-commentary.

638. Perez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. *Blood*. 2009;113(20):4977-4979. Exclude: Not intervention of interest.

639. Perez-Andreu V, Roldan V, Gonzalez-Conejero R, Hernandez-Romero D, Vicente V, Marin F. Implications of pharmacogenetics for oral anticoagulants metabolism. *Current Drug Metabolism*. 2009;10(6):632-642. Exclude: Not intervention of interest.

640. Perini JA, Struchiner CJ, Silva-Assuncao E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. *Clinical Pharmacology & Therapeutics*. 2008;84(6):722-728. Exclude: Publication type-not randomized control trial.

641. Perlstein TS, Goldhaber SZ, Nelson K, et al. The Creating an Optimal Warfarin Nomogram (CROWN) Study. *Thromb Haemost*. 2012;107(1):59-68. Exclude: Not intervention of interest.

642. Petersen CE, Ha CE, Harohalli K, Park DS, Bhagavan NV. Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. *Chemico-Biological Interactions*. 2000;124(3):161-172. Exclude: Date.

643. Pezzini A. Genetic determinants of juvenile stroke. *Thromb Res*. 2012;129(3):330-335. Exclude: Publication type-commentary.

644. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. *JAMA*. 2001;286(18):2270-2279. Exclude: Not intervention of interest.

645. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. *American Journal of Managed Care*. 2004;10(7 Pt 1):425-432. Exclude: Not intervention of interest.

646. Phillips KW, Dobesh PP, Haines ST. Considerations in using anticoagulant therapy in special patient populations. *American Journal of Health-System Pharmacy*. 2008;65(15 Suppl 7):S13-21. Exclude: Publication type-case report.

647. Piatkov I, Rochester C, Jones T, Boyages S. Warfarin toxicity and individual variability-clinical case. *Toxins*. 2010;2(11):2584-2592. Exclude: Publication type-case report.

648. Pimenoff VN, Laval G, Comas D, et al. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates. *Pharmacogenetics and Genomics*. 2012;22(12):846-857. Exclude: Publication type-not randomized control trial.

649. Pirmohamed M, Burnside G, Stoddern J, et al. A randomized trial comparing genotype-guided dosing of warfarin to standard dosing: The EU pharmacogenetics of anticoagulant therapy (EU-PACT) warfarin study. *Circulation*. 2013;128(24):2710-2711. Exclude: Publication type-conference abstract.

650. Pirmohamed M, Kamali F, Daly AK, Wadelius M. Oral anticoagulation: a critique of recent advances and controversies. *Trends in Pharmacological Sciences*. 2015;36(3):153-163. Exclude: Publication type-commentary.

651. Pocinki AG. The value of pharmacogenetic testing. *JAMA Internal Medicine*. 2015;175(2):314. Exclude: Publication type-letter.

652. Poe BL, Haverstick DM, Landers JP. Warfarin genotyping in a single PCR reaction for microchip electrophoresis. *Clinical Chemistry*. 2012;58(4):725-731. Exclude: Publication type-not randomized control trial.

653. Predazzi IM, Mango R, Norata GD, et al. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. *American Journal of Cardiovascular Drugs*. 2013;13(2):79-85. Exclude: Publication type-commentary.

654. Price ET. Warfarin pharmacogenomics and African ancestry. *Blood*. 2015;126(4):434-436. Exclude: Publication type-commentary.

655. Prows CA, Beery TA. Pharmacogenetics in critical care: atrial fibrillation as an exemplar. *Critical Care Nursing Clinics of North America.* 2008;20(2):223-231, vi-vii. Exclude: Publication type-commentary.

656. Puehringer H, Loreth RM, Klose G, et al. VKORC1 -1639G>A and CYP2C9 3 are the major genetic predictors of phenprocoumon dose requirement. *European Journal of Clinical Pharmacology.* 2010;66(6):591-598. Exclude: Publication type-not randomized control trial.

657. Quinones LA, Lavanderos MA, Cayun JP, et al. Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America. *Current Drug Metabolism.* 2014;15(2):202-208. Exclude: Publication type-not randomized control trial.

658. Qureshi SH, Yang L, Manithody C, Rezaie AR. Membrane-dependent interaction of factor Xa and prothrombin with factor Va in the prothrombinase complex. *Biochemistry.* 2009;48(22):5034-5041. Exclude: Publication type-not randomized control trial.

659. Qureshi SH, Yang L, Yegneswaran S, Rezaie AR. FRET studies with factor X mutants provide insight into the topography of the membrane-bound factor X/Xa. *Biochemical Journal.* 2007;407(3):427-433. Exclude: Publication type-not randomized control trial.

660. Radhakrishnan A, Vido D, Tayur S, Akan M, Murali S. Genotype guided therapeutic dosing of warfarin in geriatric patients. *Journal of the American College of Cardiology.* 2012;59(13 SUPPL. 1):E1696. Exclude: Publication type-conference abstract.

661. Ragia G, Kolovou V, Kolovou G, et al. A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. *Pharmacogenomics.* 2017;18(1):23-34. Exclude: No outcome of interest.

662. Raja SM, Chhablani N, Swanson R, et al. Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. *Journal of Biological Chemistry.* 2003;278(16):13688-13695. Exclude: Date.

663. Rakhra-Burris TK, Auman JT, Deverka P, et al. Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. *Pharmacogenomics.* 2010;11(1):13-21. Exclude: Publication type-not randomized control trial.

664. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. *Pharmacogenomics.* 2012;13(4):407-418. Exclude: Publication type-not randomized control trial.

665. Ramos AS, Seip RL, Rivera-Miranda G, et al. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. *Pharmacogenomics.* 2012;13(16):1937-1950. Exclude: Publication type-not randomized control trial.

666. Ramos E, Doumatey A, Elkahloun AG, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. *Pharmacogenomics Journal.* 2014;14(3):217-222. Exclude: Publication type-not randomized control trial.

667. Rasmussen MA, Skov J, Bladbjerg EM, Sidelmann JJ, Vamosi M, Jespersen J. Multivariate analysis of the relation between diet and warfarin dose. *European Journal of Clinical Pharmacology.* 2012;68(3):321-328. Exclude: Publication type-not randomized control trial.

668. Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B. CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant. *Indian Journal of Medical Research.* 2014;139(4):572-578. Exclude: Publication type-not randomized control trial.

669. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. *Clinical & Applied Thrombosis/Hemostasis.* 2004;10(2):149-154. Exclude: Date.

670. Redman AR, Zheng J, Shamsi SA, et al. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy. *Clinical & Applied Thrombosis/Hemostasis.* 2008;14(1):29-37. Exclude: Publication type-not randomized control trial.

671. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. *PLoS Medicine / Public Library of Science.* 2005;2(10):e312. Exclude: Date.

672. Remmler C, Cascorbi I. Pharmacogenomics in acute coronary syndrome. *Expert Opinion on Pharmacotherapy.* 2008;9(3):363-376. Exclude: Publication type-commentary.

673. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. *Annual Review of Pharmacology & Toxicology.* 2005;45:477-494. Exclude: Date.

674. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. *Molecular Interventions.* 2006;6(4):223-227. Exclude: Date.

675. Rezaie AR. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. *Thromb Res.* 2007;119(4):481-488. Exclude: Not intervention of interest.

676. Rezaie AR, Esmon CT. Contribution of residue 192 in factor Xa to enzyme specificity and function. *Journal of Biological Chemistry.* 1995;270(27):16176-16181. Exclude: Not intervention of interest.

677. Rhee S, Walsh K, Lewis D, Davis G, Smith KM. Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient. *Orthopedics.* 2010;33(11):828. Exclude: Not intervention of interest.

678. Rich B, Moodie EE, Stephens DA. Optimal individualized dosing strategies: A pharmacologic approach to developing dynamic treatment regimens for continuous-valued treatments. *Biometrical Journal.* 2016;58(3):502-517. Exclude: Publication type-commentary.

679. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *New England Journal of Medicine.* 2005;352(22):2285-2293. Exclude: Publication type-not randomized control trial.

680. Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. *J Thromb Haemost*. 2007;5(11):2227-2234. Exclude: Publication type-not randomized control trial.

681. Rishavy MA, Hallgren KW, Wilson LA, Usubalieva A, Runge KW, Berkner KL. The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation. *Journal of Biological Chemistry*. 2013;288(44):31556-31566. Exclude: Publication type-commentary.

682. Rodeghiero F. The revival of clinical wisdom: The case of oral anticoagulation management. *American Journal of Hematology*. 2009;84(9):546-547. Exclude: Publication type-commentary.

683. Roden DM. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? *Canadian Journal of Cardiology*. 2013;29(1):58-66. Exclude: Publication type-commentary.

684. Roden DM, Johnson JA, Kimmel SE, et al. Cardiovascular pharmacogenomics. *Circulation Research*. 2011;109(7):807-820. Exclude: Publication type-commentary.

685. Rodriguez-Velez R, Ortiz-Rivera OJ, Bower B, et al. Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. *Puerto Rico Health Sciences Journal*. 2010;29(4):402-408. Exclude: Publication type-case report.

686. Roederer MW. Cytochrome P450 enzymes and genotype-guided drug therapy. *Current Opinion in Molecular Therapeutics*. 2009;11(6):632-640. Exclude: Publication type-commentary.

687. Rogers JF, Nafziger AN, Bertino JS, Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. *American Journal of Medicine*. 2002;113(9):746-750. Exclude: Date.

688. Rojas JC, Aguilar B, Rodriguez-Maldonado E, Collados MT. Pharmacogenetics of oral anticoagulants. *Blood Coagulation & Fibrinolysis*. 2005;16(6):389-398. Exclude: Date.

689. Rolla R, Pergolini P, Vidali M, et al. Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism. *Clinical Laboratory*. 2014;60(10):1725-1733. Exclude: Publication type-not randomized control trial.

690. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. *Journal of Molecular Diagnostics*. 2010;12(3):283-291. Exclude: Not intervention of interest.

691. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. *Journal of Biological Chemistry*. 1995;270(46):27852-27858. Exclude: Not intervention of interest.

692. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. *Annals of Internal Medicine*. 2009;151(4):270-273, W295. Exclude: Publication type-commentary.

693. Ross CJ, Katzov H, Carleton B, Hayden MR. Pharmacogenomics and its implications for autoimmune disease. *Journal of Autoimmunity*. 2007;28(2-3):122-128. Exclude: Publication type-letter.

694. Ross CJ, Visscher H, Rassekh SR, et al. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. *Journal of Population Therapeutics & Clinical Pharmacology*. 2011;18:e134-151. Exclude: Publication type-commentary.

695. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. *Journal of Human Genetics*. 2010;55(9):582-589. Exclude: Publication type-not randomized control trial.

696. Ross OA, Worrall BB, Meschia JF. Advancing stroke therapeutics through genetic understanding. *Current Drug Targets*. 2007;8(7):850-859. Exclude: Publication type-commentary.

697. Ross S, Nejat S, Pare G. Use of genetic data to guide therapy in arterial disease. *J Thromb Haemost*. 2015;13 Suppl 1:S281-289. Exclude: Publication type-commentary.

698. Ross S, Pare G. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. *Pharmacogenomics*. 2013;14(13):1565-1572. Exclude: Publication type-commentary.

699. Rosskopf D, Meyer zu Schwabedissen HE, Kroemer HK, Siegmund W. [Pharmacogenomics in routine medical care]. *Deutsche Medizinische Wochenschrift*. 2010;135(4):133-144; quiz 145-136. Exclude: Publication type-commentary.

700. Roth JA, Boudreau D, Fujii MM, et al. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. *Clinical Pharmacology & Therapeutics*. 2014;95(6):636-643. Exclude: Publication type-not randomized control trial.

701. Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. *Pharmacoepidemiology & Drug Safety*. 2015;24(6):619-627. Exclude: Publication type-not randomized control trial.

702. Roth JA, Garrison LP, Jr., Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. *Public Health Genomics*. 2011;14(2):59-67. Exclude: No outcome of interest.

703. Rouse M, Cristiani C, Teng KA. Q: Should we use pharmacogenetic testing when prescribing warfarin? *Cleveland Clinic Journal of Medicine*. 2013;80(8):483-486. Exclude: Publication type-commentary.

704. Ruano G, Bower B. The pharmacogenomics of warfarin (Coumadin) administration. *Connecticut Medicine*. 2006;70(4):251-252. Exclude: Date.

705. Rubio-Terres C, Soria JM, Morange PE, et al. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism. *Applied Health Economics & Health Policy*. 2015;13(2):233-242. Exclude: Not intervention of interest.

706. Rudolph AE, Porche-Sorbet R, Miletich JP. Substitution of asparagine for arginine 347 of recombinant factor Xa markedly reduces factor Va binding. *Biochemistry*. 2000;39(11):2861-2867. Exclude: Date.

707. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. *American Journal of Hematology*. 2002;71(1):1-6. Exclude: Date.

708. Rumilla K, Chen D, Baudhuin LM. Pharmacogenetics in hemostasis: friend or foe? *Seminars in Thrombosis & Hemostasis*. 2009;35(1):42-49. Exclude: Publication type-commentary.

709. Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. *European Journal of Clinical Pharmacology*. 2013;69(3):395-405. Exclude: Publication type-not randomized control trial.

710. Ruzickova T, Sramek M, Lacinova Z, et al. Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients. *European Stroke Journal*. 2016;1(Suppl 1):413-414. Exclude: Publication type-conference abstract.

711. Ryan A, Nevitt SJ, Cook P. Bile acid sequestrants for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. *Cochrane Database of Systematic Reviews*. 2017(12). Exclude: Not intervention of interest.

712. Ryan F, Byrne S, O'Shea S. Managing oral anticoagulation therapy: improving clinical outcomes. A review. *Journal of Clinical Pharmacy & Therapeutics*. 2008;33(6):581-590. Exclude: Publication type-not systematic review.

713. Sadee W. Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. *Journal of Pharmaceutical Sciences*. 2013;102(9):2924-2929. Exclude: Publication type-commentary.

714. Sadrai S, Ghadam P, Sharifian R, Sadeghian F. Assaying of warfarin in Iranian warfarin resistance patients blood by HPLC. *Pakistan Journal of Biological Sciences*. 2008;11(4):683-685. Exclude: Publication type-not randomized control trial.

715. Sagreiya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.[Erratum appears in Pharmacogenet Genomics. 2010 Oct;20(10):645 Note: Sagrieya, Hersh [corrected to Sagreiya, Hersh]]. *Pharmacogenetics and Genomics*. 2010;20(7):407-413. Exclude: Publication type-not randomized control trial.

716. Saini A, Spinella PC. Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation. *Clinics in Laboratory Medicine*. 2014;34(3):655-673. Exclude: Not intervention of interest.

717. Saito R, Takeda K, Yamamoto K, et al. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake. *J Thromb Thrombolys*. 2014;38(1):105-114. Exclude: Not intervention of interest.

718. Salari K, Watkins H, Ashley EA. Personalized medicine: hope or hype? *European Heart Journal*. 2012;33(13):1564-1570. Exclude: Publication type-commentary.

719. Salinger DH, Shen DD, Thummel K, Wittkowsky AK, Vicini P, Veenstra DL. Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. *Pharmacogenetics and Genomics*. 2009;19(12):965-971. Exclude: Publication type-not randomized control trial.

720. Samama MM, Meddahi S, Samama CM. Pharmacology and laboratory testing of the oral Xa inhibitors. *Clinics in Laboratory Medicine*. 2014;34(3):503-517. Exclude: Not intervention of interest.

721. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. *Molecular Diagnosis & Therapy*. 2013;17(3):165-184. Exclude: Publication type-commentary.

722. Saminathan R, Bai J, Sadrolodabaee L, et al. VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker. *PLoS ONE [Electronic Resource]*. 2010;5(12):e15064. Exclude: Publication type-not randomized control trial.

723. Sanchez-Diz P, Estany-Gestal A, Aguirre C, et al. Prevalence of CYP2C9 polymorphisms in the south of Europe.[Erratum appears in Pharmacogenomics J. 2010 Jun;10(3):243]. *Pharmacogenomics Journal*. 2009;9(5):306-310. Exclude: Not intervention of interest.

724. Sandanaraj E, Lal S, Cheung YB, et al. VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. *Drug Metabolism & Pharmacokinetics*. 2009;24(4):365-375. Exclude: Publication type-not randomized control trial.

725. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. *Genetics in Medicine*. 2005;7(2):97-104. Exclude: Not intervention of interest.

726. Santos PC, Marcatto LR, Duarte NE, et al. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. *Pharmacogenomics*. 2015;16(8):865-876. Exclude: Publication type-not randomized control trial.

727. Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.[Erratum appears in J Clin Pharm Ther. 2008 Feb;33(1):93 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected]. *Journal of Clinical Pharmacy & Therapeutics*. 2007;32(6):641-649. Exclude: Publication type-not randomized control trial.

728. Sasaki T, Tabuchi H, Higuchi S, Ieiri I. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. *Pharmacogenomics*. 2009;10(8):1257-1266. Exclude: Publication type-not randomized control trial.

729. Schaafhausen A, Rost S, Oldenburg J, Muller CR. Identification of VKORC1 interaction partners by split-ubiquitin system and coimmunoprecipitation. *Thromb Haemost*. 2011;105(2):285-294. Exclude: Publication type-not randomized control trial.

730. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. *Clinical Pharmacology & Therapeutics*. 2006;80(1):13-22. Exclude: Publication type-not randomized control trial.

731. Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. *Current Pharmaceutical Design*. 2010;16(2):187-203. Exclude: Publication type-commentary.

732. Schildcrout JS, Shi Y, Danciu I, et al. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. *Journal of Clinical Epidemiology*. 2016;72:107-115. Exclude: Publication type-not randomized control trial.

733. Schinzel H, Nitschmann S. [Anticoagulation with warfarin]. *Internist*. 2009;50(8):1026-1028. Exclude: Not English.

734. Schuliga M, Jaffar J, Berhan A, et al. Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. *American Journal of Physiology - Lung Cellular & Molecular Physiology*. 2017;312(5):L772-L782. Exclude: Not intervention of interest.

735. Schulman S. Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. *Seminars in Thrombosis & Hemostasis*. 2015;41(2):160-165. Exclude: Publication type-commentary.

736. Schwab M, Schaeffeler E. Warfarin pharmacogenetics meets clinical use. *Blood*. 2011;118(11):2938-2939. Exclude: Publication type-commentary.

737. Schwartz JB, Kane L, Moore K, Wu AH. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. *Journal of the American Medical Directors Association*. 2011;12(9):633-638. Exclude: No outcome of interest.

738. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. *European Journal of Clinical Investigation*. 2003;33 Suppl 2:23-30. Exclude: Date.

739. Schwer C, Lamana S, Dasanu CA. Hematology consult: high-sensitivity warfarin genotype. *Connecticut Medicine*. 2013;77(10):581-585. Exclude: Publication type-case report.

740. Scibona P, Angriman F, Simonovich V, Heller MM, Belloso WH. [Cardiovascular pharmacogenomics]. *Archivos de Cardiologia de Mexico*. 2014;84(1):25-31. Exclude: Publication type-commentary.

741. Scibona P, Redal MA, Garfi LG, Arbelbide J, Argibay PF, Belloso WH. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants. *Genetics & Molecular Research*. 2012;11(1):70-76. Exclude: Publication type-not randomized control trial.

742. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. *Blood*. 2005;106(7):2329-2333. Exclude: No outcome of interest.

743. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. *Clinical Pharmacology & Therapeutics*. 2002;72(6):702-710. Exclude: Date.

744. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. *American Journal of Human Genetics*. 2008;82(2):495-500. Exclude: Not intervention of interest.

745. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9 8 is prevalent among African-Americans: implications for pharmacogenetic dosing. *Pharmacogenomics*. 2009;10(8):1243-1255. Exclude: Publication type-not randomized control trial.

746. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. *Pharmacogenomics*. 2010;11(6):781-791. Exclude: Publication type-not randomized control trial.

747. Scott SA, Lubitz SA. Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? *Pharmacogenomics*. 2014;15(6):719-722. Exclude: Publication type-commentary.

748. Seeringer A, Kirchheiner J. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?]. *Internist*. 2008;49(7):877-883. Exclude: Publication type-commentary.

749. Seip RL, Duconge J, Ruano G. Implementing genotype-guided antithrombotic therapy. *Future Cardiology*. 2010;6(3):409-424. Exclude: Publication type-commentary.

750. Self TH, Oliphant CS, Reaves AB, Richardson AM, Sands CW. Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms. *Thromb Res*. 2015;135(1):5-8. Exclude: Not intervention of interest.

751. Self TH, Wallace JL, Sakaan S, Sands CW. Effect of Body Weight on Dose of Vitamin K Antagonists. *Southern Medical Journal*. 2015;108(10):637-643. Exclude: Publication type-commentary.

752. Shahabi P, Dube MP. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. *International Journal of Cardiology*. 2015;184:772-795. Exclude: Publication type-commentary.

753. Shahabi P, Siest G, Visvikis-Siest S. Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin. *Pharmacogenomics*. 2012;13(11):1215-1218. Exclude: Publication type-commentary.

754. Shahin MH, Cavallari LH, Perera MA, et al. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Thromb Haemost*. 2013;109(6):1045-1050. Exclude: Publication type-not randomized control trial.

755. Shahin MH, Johnson JA. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? *Current Opinion in Cardiology*. 2013;28(3):305-314. Exclude: Publication type-commentary.

756. Shalia KK, Doshi SM, Parikh S, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. *Journal of the Association of Physicians of India*. 2012;60:34-38. Exclude: Publication type-not randomized control trial.

757. Sharabiani A, Bress A, Douzali E, Darabi H. Revisiting Warfarin Dosing Using Machine Learning Techniques. *Computational & Mathematical Methods in Medicine*. 2015;2015:560108. Exclude: Publication type-not randomized control trial.

758. Shaul C, Blotnick S, Muszkat M, Bialer M, Caraco Y. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. *Molecular Diagnosis & Therapy*. 2017;21(1):75-83. Exclude: No outcome of interest.

759. Shaw K, Amstutz U, Castro-Pastrana L, et al. Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT. *Journal of Population Therapeutics & Clinical Pharmacology*. 2013;20(2):e110-127. Exclude: Publication type-not randomized control trial.

760. Shaw K, Amstutz U, Hildebrand C, et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. *Pediatric Blood & Cancer*. 2014;61(6):1055-1062. Exclude: Publication type-not randomized control trial.

761. Shaw K, Amstutz U, Kim RB, et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. *Therapeutic Drug Monitoring*. 2015;37(4):428-436. Exclude: Publication type-not systematic review.

762. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. *J Thromb Thrombolys*. 2010;30(2):220-225. Exclude: Not intervention of interest.

763. Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 1999;19(10):1153-1158. Exclude: Date.

764. Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. *CNS Drugs*. 2008;22(10):815-825. Exclude: Not intervention of interest.

765. Shi C, Yan W, Wang G, Wang F, Li Q, Lin N. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. *PLoS ONE [Electronic Resource]*. 2015;10(12):e0144511. Exclude: Individual studies from systematic review are included.

766. Shi J, Wang X, Nguyen JH, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. *Biochemical Pharmacology*. 2016;119:76-84. Exclude: Publication type-not randomized control trial.

767. Shiffman D, Perez MV, Bare LA, Louie JZ, Arellano AR, Devlin JJ. Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. *BMC Cardiovascular Disorders*. 2015;15:104. Exclude: Not intervention of interest.

768. Shil AB, Strohm MP. Warfarin pharmacogenetics. *New England Journal of Medicine*. 2009;360(23):2474-2475; author reply 2475. Exclude: Publication type-letter.

769. Shin J. Clinical pharmacogenomics of warfarin and clopidogrel. *Journal of Pharmacy Practice*. 2012;25(4):428-438. Exclude: Publication type-commentary.

770. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. *Pharmacogenomics*. 2011;12(1):125-134. Exclude: Not intervention of interest.

771. Shin J, Kayser SR. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2011;31(9):863-870. Exclude: Not intervention of interest.

772. Shrif NE, Won HH, Lee ST, et al. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. *European Journal of Clinical Pharmacology*. 2011;67(11):1119-1130. Exclude: Publication type-not randomized control trial.

773. Shu WY, Li JL, Wang XD, Huang M. Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. *Zhongguo Yao Li Xue Bao/Acta Pharmacologica Sinica*. 2015;36(5):535-543. Exclude: Publication type-not systematic review.

774. Shuen AY, Wong BY, Fu L, Selby R, Cole DE. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. *Clinical Biochemistry*. 2012;45(6):397-401. Exclude: Publication type-not randomized control trial.

775. Shurin SB, Nabel EG. Pharmacogenomics--ready for prime time? *New England Journal of Medicine*. 2008;358(10):1061-1063. Exclude: Publication type-commentary.

776. Sidiropoulos N, Wu AH. Clinical trials for pharmacogenomics testing for warfarin dosing: relevance to general community practices. *Genetics in Medicine*. 2011;13(6):505-508. Exclude: Publication type-commentary.

777. Siguret V. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy]. *Pathologie Biologie*. 2007;55(6):295-298. Exclude: Not English.

778. Siguret V, Pautas E, Gouin-Thibault I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. *Vitamins & Hormones*. 2008;78:247-264. Exclude: Publication type-commentary.

779. Singh A. Pharmacogenomics--the potential of genetically guided prescribing. *Australian Family Physician*. 2007;36(10):820-824. Exclude: Publication type-commentary.

780. Singh LS, Bukys MA, Beck DO, Kalafatis M. Amino acids Glu323, Tyr324, Glu330, and Val331 of factor Va heavy chain are essential for expression of cofactor activity. *Journal of Biological Chemistry*. 2003;278(30):28335-28345. Exclude: Date.

781. Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. *Drug Metabolism & Pharmacokinetics*. 2011;26(2):130-136. Exclude: Publication type-not randomized control trial.

782. Sinxadi P, Blockman M. Warfarin resistance. *Cardiovascular Journal of Africa*. 2008;19(4):215-217. Exclude: Publication type-commentary.

783. Sipeky C, Melegh B. [Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy]. *Orvosi Hetilap*. 2008;149(39):1839-1844. Exclude: Not English.

784. Sipeky C, Weber A, Melegh BI, et al. Interethnic variability of CYP4F2 (V433M) in admixed population of Roma and Hungarians. *Environmental Toxicology & Pharmacology*. 2015;40(1):280-283. Exclude: Publication type-not randomized control trial.

785. Skjoth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. *Thromb Haemost*. 2014;111(5):981-988. Exclude: Not intervention of interest.

786. Skov J, Bladbjerg EM, Rasmussen MA, Sidelmann JJ, Leppin A, Jespersen J. Genetic, clinical and behavioural determinants of vitamin K-antagonist dose--explored through multivariable modelling and visualization. *Basic & Clinical Pharmacology & Toxicology*. 2012;110(2):193-198. Exclude: Publication type-not randomized control trial.

787. Slavkin HC. Benefits and risks of medications: challenges for the 21st century. *Journal of the American Dental Association*. 1997;128(8):1157-1160. Exclude: Date.

788. Smith BP, Best DH, Elliott CG. Genetics and pharmacogenomics in pulmonary arterial hypertension. *Heart Failure Clinics*. 2012;8(3):319-330. Exclude: Publication type-commentary.

789. Smith DM, Cristiani C, Teng KA, Hicks JK. To the Editor: Clinical utility of warfarin pharmacogenomics. *Cleveland Clinic Journal of Medicine*. 2015;82(5):268-269. Exclude: Publication type-letter.

790. Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. *Thromb Haemost*. 2008;100(3):447-452. Exclude: Publication type-commentary.

791. Smolik S, Moric-Janiszewska E, Weglarz L. CYP2C9 gene polymorphism in the pharmacological treatment of long QT patients. *Acta Poloniae Pharmaceutica*. 2014;71(6):1103-1106. Exclude: Publication type-commentary.

792. Soares RA, Santos PC, Machado-Coelho GL, et al. CYP2C9 and VKORC1 polymorphisms are differently distributed in the Brazilian population according to self-declared ethnicity or genetic ancestry. *Genetic Testing & Molecular Biomarkers*. 2012;16(8):957-963. Exclude: Publication type-not randomized control trial.

793. Solomon HM. Variations in metabolism of coumarin anticoagulant drugs. *Annals of the New York Academy of Sciences*. 1968;151(2):932-935. Exclude: Date.

794. Sominsky S, Korostishevsky M, Kurnik D, et al. The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. *Journal of Applied Genetics*. 2014;55(2):163-171. Exclude: Publication type-not randomized control trial.

795. Somogy A. Evolution of pharmacogenomics. *Proceedings of the Western Pharmacology Society*. 2008;51:1-4. Exclude: Publication type-commentary.

796. Sorich MJ, McKinnon RA. Personalized medicine: potential, barriers and contemporary issues. *Current Drug Metabolism*. 2012;13(7):1000-1006. Exclude: Publication type-commentary.

797. Spigset O. [Pharmacogenetics in practice]. *Tidsskrift for Den Norske Laegeforening*. 2008;128(15):1679. Exclude: Not English.

798. Spohn G, Geisen C, Luxembourg B, Sittinger K, Seifried E, Bonig H. Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics.[Erratum appears in Mol Diagn Ther. 2011 Jun 1;15(3):142-4]. *Molecular Diagnosis & Therapy*. 2011;15(1):13-19. Exclude: Publication type-not randomized control trial.

799. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database of Systematic Reviews*. 2017(4). Exclude: Not intervention of interest.

800. Stack G, Education Committee of the Academy of Clinical Laboratory P, Scientists. Pathology consultation on warfarin pharmacogenetic testing. *American Journal of Clinical Pathology*. 2011;135(1):13-19. Exclude: Publication type-commentary.

801. Stack G, Maurice CB. Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials. *American Journal of Clinical Pathology*. 2016;145(5):671-686. Exclude: Publication type-not randomized control trial.

802. Stafford DW. The vitamin K cycle. *J Thromb Haemost*. 2005;3(8):1873-1878. Exclude: Date.

803. Stankov KM, Stanimirov BG, Mikov MM. Pharmacogenomic Determinants of Response to Cardiovascular Drugs. *Medicinski Pregled*. 2015;68(7-8):259-265. Exclude: Publication type-commentary.

804. Stanley TB, Humphries J, High KA, Stafford DW. Amino acids responsible for reduced affinities of vitamin K-dependent propeptides for the carboxylase. *Biochemistry*. 1999;38(47):15681-15687. Exclude: Date.

805. Starner CI, Ritter S, Wickersham P, Phillips J, Gleason PP. Warfarin pharmacogenomics testing: Prevalence, timeliness, and cost. *Journal of managed care pharmacy.* 2012;18(2):205. Exclude: Publication type-conference abstract.

806. Stearns-Kurosawa DJ, Swindle K, D'Angelo A, et al. Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. *Blood.* 2002;99(2):526-530. Exclude: Date.

807. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. *Clinical Pharmacokinetics.* 2008;47(9):565-594. Exclude: Not intervention of interest.

808. Stepien E, Branicka A, Ciesla-Dul M, Undas A. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists. *Journal of Applied Genetics.* 2009;50(4):399-403. Exclude: Publication type-not randomized control trial.

809. Stepien E, Wypasek E, Branicka A, Undas A. [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms]. *Kardiologia Polska.* 2010;68 Suppl 5:S428-435. Exclude: Publication type-commentary.

810. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. *JAMA Intern Med.* 2014;174(8):1330-1338. Exclude: Individual studies from systematic review are included.

811. Stingl JC, Kaumanns KL, Claus K, et al. Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial. *BMC Family Practice.* 2016;17:49. Exclude: No outcome of interest.

812. Stojiljkovic M, Patrinos GP, Pavlovic S. Clinical applicability of sequence variations in genes related to drug metabolism. *Current Drug Metabolism.* 2011;12(5):445-454. Exclude: Publication type-commentary.

813. Stolz E, Kemkes-Matthes B, Potzsch B, et al. Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. *Acta Neurologica Scandinavica.* 2000;102(1):31-36. Exclude: Date.

814. Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P. Pharmacogenomics of Oral Antithrombotic Drugs. *Current Pharmaceutical Design.* 2016;22(13):1933-1949. Exclude: Publication type-not systematic review.

815. Suarez-Kurtz G, Amorim A, Damasceno A, et al. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. *Pharmacogenomics.* 2010;11(9):1257-1267. Exclude: Not intervention of interest.

816. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. *British Journal of Clinical Pharmacology.* 2013;75(2):334-346. Exclude: Not intervention of interest.

817. Suarez-Kurtz G, Botton MR. Pharmacogenetics of coumarin anticoagulants in Brazilians. *Expert Opinion On Drug Metabolism & Toxicology*. 2015;11(1):67-79. Exclude: Publication type-commentary.

818. Suarez-Kurtz G, Paula DP, Struchiner CJ. Pharmacogenomic implications of population admixture: Brazil as a model case. *Pharmacogenomics*. 2014;15(2):209-219. Exclude: Publication type-commentary.

819. Supe S, Bozina N, Matijevic V, et al. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. *Journal of the Neurological Sciences*. 2014;343(1-2):30-35. Exclude: Publication type-not randomized control trial.

820. Supe S, Poljakovic Z, Bozina T, Ljevak J, Macolic Sarinic V, Bozina N. Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. *Archives of Medical Research*. 2015;46(4):265-273. Exclude: Publication type-not randomized control trial.

821. Suppa M, Migliozzi E, Magnanelli E, et al. [A prompt diagnosis of Steinert's dystrophy in emergency unit]. *Clinica Terapeutica*. 2012;163(6):463-466. Exclude: Not English.

822. Suriapranata IM, Tjong WY, Wang T, et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. *BMC Medical Genetics*. 2011;12:80. Exclude: Publication type-not randomized control trial.

823. Sutphin SD, Smith KM. Pharmacogenomics-Potential applications to orthopedic practice. *Orthopedics*. 2005;28(10):1157-1159. Exclude: Date.

824. Sweet K, Gordon ES, Sturm AC, et al. Design and implementation of a randomized controlled trial of genomic counseling for patients with chronic disease. *Journal of Personalized Medicine*. 2014;4(1):1-19. Exclude: No outcome of interest.

825. Sychev DA, Antonov IM, Ignat'ev IV, et al. [Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study]. *Kardiologiia*. 2010;50(5):42-46. Exclude: Not English.

826. Sychev DA, Antonov IM, Kropacheva ES, Panchenko EP. [Which of algorithms of warfarin dosing based on results of pharmacogenetic testing is suitable for patients in Russia]. *Kardiologiia*. 2010;50(4):35-37. Exclude: Not English.

827. Sychev DA, Ivashchenko DV, Rusin IV. [Impact of pharmacogenetic testing on the risk of bleedings and excessive hypocoagulation episodes in the use of warfarin: the first meta-analysis of Russian prospective studies]. *Terapevticheskii Arkhiv*. 2014;86(4):64-71. Exclude: Not English.

828. Syn NL, Lee SC, Brunham LR, Goh BC. Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation. *Pharmacogenetics and Genomics*. 2015;25(10):491-500. Exclude: Publication type-not randomized control trial.

829. Szorady I, Santa A. Pharmacogenetically hazardous drugs: a proposed new scoring method. *Acta Physiologica Hungarica*. 1991;77(3-4):305-318. Exclude: Date.

830. Tabrizi AR, McGrath SD, Blinder MA, Buchman TG, Zehnbauer BA, Freeman BD. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms. *American Journal of Hematology.* 2001;67(2):144-146. Exclude: Date.

831. Tadros R, Shakib S. Clot prevention--common questions about medications. *Australian Family Physician.* 2010;39(7):480-483. Exclude: Publication type-commentary.

832. Tai G, Farin F, Rieder MJ, et al. In-vitro and in-vivo effects of the CYP2C9 11 polymorphism on warfarin metabolism and dose. *Pharmacogenetics and Genomics.* 2005;15(7):475-481. Exclude: Date.

833. Takahashi H. [Warfarin resistance and related pharmacogenetic information]. *Brain & Nerve / Shinkei Kenkyu no Shinpo.* 2008;60(11):1365-1371. Exclude: Publication type-commentary.

834. Takahashi H. [Pharmacogenetics of warfarin: clinical implications]. *Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics.* 2010;47(1):38-40. Exclude: Not English.

835. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. *Clinical Pharmacokinetics.* 2001;40(8):587-603. Exclude: Date.

836. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. *Pharmacogenomics Journal.* 2003;3(4):202-214. Exclude: Date.

837. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. *Clinical Pharmacology & Therapeutics.* 1998;63(5):519-528. Exclude: Not intervention of interest.

838. Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. *Pharmacogenetics.* 1998;8(5):365-373. Exclude: Not intervention of interest.

839. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. *Clinical Pharmacology & Therapeutics.* 2003;73(3):253-263. Exclude: Date.

840. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. *Pharmacogenetics and Genomics.* 2006;16(2):101-110. Exclude: Date.

841. Takahashi H, Wilkinson GR, Padrini R, Echizen H. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. *Clinical Pharmacology & Therapeutics.* 2004;75(5):376-380. Exclude: Date.

842. Takeuchi F, Kashida M, Okazaki O, et al. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. *Circulation Journal.* 2010;74(5):977-982. Exclude: Not intervention of interest.

843. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. *PLoS Genetics*. 2009;5(3):e1000433. Exclude: Publication type-not randomized control trial.

844. Tan D, Zeng J. Clinical evaluation of warfarin pharmacogenetics algorithms application. *Cardiology*. 2012;123(9). Exclude: Publication type-conference abstract.

845. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. *Pharmacogenomics*. 2010;11(3):439-448. Exclude: Publication type-commentary.

846. Tan SL, Li Z, Song GB, et al. Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. *Pharmazie*. 2012;67(11):930-937. Exclude: Not intervention of interest.

847. Tan Y, Hu Y, Liu X, Yin Z, Chen XW, Liu M. Improving drug safety: from adverse drug reaction knowledge discovery to clinical implementation. *Methods*. 2016;110:14-25. Exclude: Not intervention of interest.

848. Tang HL, Shi WL, Li XG, Zhang T, Zhai SD, Xie HG. Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. *Pharmacogenomics J*. 2015;15(6):496-504. Exclude: Individual studies from systematic review are included.

849. Tang Q, Zou H, Guo C, Liu Z. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis. *Int J Cardiol*. 2014;175(3):587-591. Exclude: Publication type-letter.

850. Tang T, Liu J, Zuo K, et al. Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials. *J Cardiovasc Pharm T*. 2015;20(4):387-394. Exclude: Individual studies from systematic review are included.

851. Tang W, Shi QP, Ding F, Yu ML, Hua J, Wang YX. Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies. *International Journal of Clinical Pharmacology & Therapeutics*. 2017;55(4):304-321. Exclude: Not intervention of interest.

852. Tanira MO, Al-Mukhaini MK, Al-Hinai AT, Al Balushi KA, Ahmed IS. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. *Community Genetics*. 2007;10(1):32-37. Exclude: Not intervention of interest.

853. Tassies D. Pharmacogenetics of antithrombotic drugs. *Current Pharmaceutical Design*. 2006;12(19):2425-2435. Exclude: Date.

854. Teagarden JR. Warfarin and pharmacogenomic testing: what would Pascal do? *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2009;29(3):245-247. Exclude: Publication type-commentary.

855. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically

guided dosing. *Clinical Pharmacokinetics*. 2007;46(3):187-208. Exclude: Publication type-commentary.

856. Thacker SM, Grice GR, Milligan PE, Gage BF. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. *J Thromb Haemost*. 2008;6(9):1445-1449. Exclude: Publication type-commentary.

857. Tham LS, Goh BC, Nafziger A, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. *Clinical Pharmacology & Therapeutics*. 2006;80(4):346-355. Exclude: Publication type-not randomized control trial.

858. Thareja G, John SE, Hebbar P, Behbehani K, Thanaraj TA, Alsmadi O. Sequence and analysis of a whole genome from Kuwaiti population subgroup of Persian ancestry. *BMC Genomics*. 2015;16:92. Exclude: Publication type-not randomized control trial.

859. Thigpen JL, Limdi NA. Reversal of oral anticoagulation. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2013;33(11):1199-1213. Exclude: Not intervention of interest.

860. Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. *Current Topics in Medicinal Chemistry*. 2004;4(13):1399-1409. Exclude: Date.

861. Thompson CA. FDA encourages genetics-aided warfarin dosing. *American Journal of Health-System Pharmacy*. 2007;64(19):1994-1996. Exclude: Publication type-commentary.

862. Thornburg CD, Jones E, Bomgaars L, Gage BF. Pediatric warfarin practice and pharmacogenetic testing. *Thromb Res*. 2010;126(2):e144-146. Exclude: Publication type-letter.

863. Thyzel E, Siegling S, Brinkmann T, Kleesiek K, Gotting C. Expression and characterization of wild-type TFPI and the [P151L]TFPI mutant in insect cells. *Molecular & Cellular Biochemistry*. 2006;283(1-2):31-38. Exclude: Not intervention of interest.

864. Tomek A, Matoska V, Eisert C, Serebruany VL. Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations. *American Journal of Therapeutics*. 2011;18(3):e55-66. Exclude: Publication type-commentary.

865. Tomek A, Mat'oska V, Kumstyrfova T, Taborsky L. [Application of warfarin pharmacogenetics]. *Vnitrni Lekarstvi*. 2009;55(6):565-569. Exclude: Publication type-commentary.

866. Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. *Clinical Chemistry & Laboratory Medicine*. 2004;42(1):72-78. Exclude: Date.

867. Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. *Clinical Pharmacology & Therapeutics*. 2014;95(3):281-293. Exclude: Publication type-commentary.

868. Ueno K. [Application of clinical pharmacokinetics to clinical toxicology]. *Chudoku Kenkyu: Chudoku Kenky Ukai Jun Kikanshi*. 2012;25(1):3-10. Exclude: Not English.

869. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. *Clinical Pharmacokinetics*. 2005;44(12):1227-1246. Exclude: Not intervention of interest.

870. Ufer M, Kammerer B, Kahlich R, et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. *Xenobiotica*. 2004;34(9):847-859. Exclude: Date.

871. Ungerer LL, Pestka EL, Messner PK. Using genetic testing to guide warfarin therapy. *Nursing*. 2012;42(5):63-65. Exclude: Publication type-commentary.

872. Uno T, Sugimoto K, Sugawara K, Tateishi T. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. *Journal of Clinical Pharmacy & Therapeutics*. 2008;33(1):67-73. Exclude: Not intervention of interest.

873. Valentin, II, Rivera G, Nieves-Plaza M, et al. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. *Puerto Rico Health Sciences Journal*. 2014;33(3):97-104. Exclude: Not intervention of interest.

874. Valentin, II, Vazquez J, Rivera-Miranda G, et al. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. *Annals of Pharmacotherapy*. 2012;46(2):208-218. Exclude: Publication type-not randomized control trial.

875. van der Meer FJ, Vos HL, Rosendaal FR. No indication for APTT screening in patients on oral anticoagulant therapy. *Thromb Haemost*. 1999;81(3):364-366. Exclude: Date.

876. Van Horn WD. Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1. *Critical Reviews in Biochemistry & Molecular Biology*. 2013;48(4):357-372. Exclude: Publication type-commentary.

877. van Ryn J, Grottke O, Spronk H. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. *Clinics in Laboratory Medicine*. 2014;34(3):479-501. Exclude: Not intervention of interest.

878. van Schie RM, el Khedr N, Verhoef TI, et al. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. *Pharmacogenomics*. 2012;13(11):1239-1245. Exclude: Publication type-not randomized control trial.

879. van Schie RM, Jorgensen AL, de Boer A, Maitland-van der Zee AH, group E-Ps. Systematic review of pharmacogenetic warfarin dosing. *Journal of General Internal Medicine*. 2009;24(10):1171. Exclude: Publication type-letter.

880. van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. *Pharmacogenomics*. 2009;10(10):1687-1695. Exclude: No outcome of interest.

881. van Schie RM, Wessels JA, le Cessie S, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic

data.[Erratum appears in Eur Heart J. 2013 Jun;34(24):1854]. *European Heart Journal*. 2011;32(15):1909-1917. Exclude: Not intervention of interest.

882. Vandell AG, Lee J, Shi M, Rubets I, Brown KS, Walker JR. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. *Pharmacogenomics journal*. 2016(pagination). Exclude: Not intervention of interest.

883. Vandell AG, Walker J, Brown KS, et al. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. *Heart*. 2017;103(22):1800-1805. Exclude: Not intervention of interest.

884. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? *BMJ*. 1996;313(7065):1127-1130. Exclude: Date.

885. Vasku A. [Application of warfarin pharmacogenetics]. *Vnitrni Lekarstvi*. 2009;55(6):541. Exclude: Not English.

886. Vear SI, Ayers GD, Van Driest SL, Sidonio RF, Stein CM, Ho RH. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. *British Journal of Haematology*. 2014;165(6):832-835. Exclude: Publication type-not randomized control trial.

887. Vear SI, Stein CM, Ho RH. Warfarin pharmacogenomics in children. *Pediatric Blood & Cancer*. 2013;60(9):1402-1407. Exclude: Publication type-commentary.

888. Vecsler M, Loebstein R, Almog S, et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. *Thromb Haemost*. 2006;95(2):205-211. Exclude: Date.

889. Veenstra DL. The cost-effectiveness of warfarin pharmacogenomics. *J Thromb Haemost*. 2007;5(9):1974-1975. Exclude: Publication type-letter.

890. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. *Aaps Pharmsci*. 2000;2(3):E29. Exclude: Not intervention of interest.

891. Veenstra DL, Roth JA, Garrison LP, Jr., Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. *Genetics in Medicine*. 2010;12(11):686-693. Exclude: No outcome of interest.

892. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N Engl J Med*. 2013;369(24):2304-2312. Exclude: Not intervention of interest.

893. Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. *British Journal of Clinical Pharmacology*. 2014;77(4):626-641. Exclude: Publication type-commentary.

894. Verhoef TI, Redekop WK, van Schie RM, et al. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. *Pharmacogenomics*. 2012;13(12):1405-1417. Exclude: Publication type-not systematic review.

895. Verhoef TI, Redekop WK, Veenstra DL, et al. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. *Pharmacogenomics*. 2013;14(8):869-883. Exclude: Not intervention of interest.

896. Verstuyft C, Delavenne X, Rousseau A, et al. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. *Clinical Pharmacokinetics*. 2012;51(1):41-53. Exclude: Not intervention of interest.

897. Vesell ES. Recent progress in pharmacogenetics. *Advances in Pharmacology*. 1969;7:1-52. Exclude: Date.

898. Vesell ES. Advances in pharmacogenetics. *Progress in Medical Genetics*. 1973;9:291-367. Exclude: Date.

899. Villagra D, Duconge J, Windemuth A, et al. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. *Clinica Chimica Acta*. 2010;411(17-18):1306-1311. Exclude: Publication type-not randomized control trial.

900. Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. *Journal of Cardiovascular Pharmacology*. 2011;58(3):228-239. Exclude: Publication type-commentary.

901. Vladutiu GD. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality? *Molecular Genetics & Metabolism*. 2008;93(1):1-4. Exclude: Publication type-commentary.

902. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. *Thromb Haemost*. 2005;93(4):700-705. Exclude: Publication type-not randomized control trial.

903. Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. *Journal of the American College of Cardiology*. 2012;60(1):9-20. Exclude: Publication type-commentary.

904. Voora D, McLeod HL, Eby C, Gage BF. Use of pharmacogenetics to guide warfarin therapy. *Drugs of Today*. 2004;40(3):247-257. Exclude: Date.

905. Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. *Pharmacogenomics*. 2005;6(5):503-513. Exclude: Date.

906. Wadelius M. Point: use of pharmacogenetics in guiding treatment with warfarin. *Clinical Chemistry*. 2009;55(4):709-711. Exclude: Publication type-commentary.

907. Wadelius M. Warfarin pharmacogenetics: it matters if you're black or white. *Blood*. 2014;124(14):2171. Exclude: Publication type-commentary.

908. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting.[Erratum appears in Blood. 2014 Feb 13;123(7):1113]. *Blood*. 2009;113(4):784-792. Exclude: Not intervention of interest.

909. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. *Pharmacogenomics Journal*. 2007;7(2):99-111. Exclude: Publication type-commentary.

910. Wakamiya T, Hokosaki T, Tsujimoto S, et al. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.[Erratum appears in Mol Diagn Ther. 2016 Oct;20(5):501; PMID: 27384761]. *Molecular Diagnosis & Therapy*. 2016;20(4):393-400. Exclude: Publication type-not randomized control trial.

911. Walker CH. Biochemical biomarkers in ecotoxicology--some recent developments. *Science of the Total Environment*. 1995;171(1-3):189-195. Exclude: Date.

912. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. *Current Drug Metabolism*. 2009;10(7):781-834. Exclude: Publication type-commentary.

913. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.[Erratum appears in Blood. 2009 Feb 5;113(6):1393-4]. *Blood*. 2008;112(4):1013-1021. Exclude: Not intervention of interest.

914. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. *New England Journal of Medicine*. 2011;364(12):1144-1153. Exclude: Publication type-commentary.

915. Wang Z, Wang M, Lazo JS, Carr BI. Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. *Journal of Biological Chemistry*. 2002;277(22):19470-19475. Exclude: Date.

916. Wang ZQ, Zhang R, Zhang PP, et al. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials. *J Cardiovasc Pharm*. 2015;65(4):364-370. Exclude: Individual studies from systematic review are included.

917. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Jr., Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. *Journal of Clinical Investigation*. 1995;95(4):1773-1781. Exclude: Date.

918. Weeke P, Roden DM. Pharmacogenomics and cardiovascular disease. *Current Cardiology Reports*. 2013;15(7):376. Exclude: Publication type-commentary.

919. Weeke P, Roden DM. Applied pharmacogenomics in cardiovascular medicine. *Annual Review of Medicine*. 2014;65:81-94. Exclude: Publication type-commentary.

920. Wei M, Ye F, Xie D, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. *Thromb Haemost*. 2012;107(6):1083-1091. Exclude: Publication type-not randomized control trial.

921. Wells PS, Majeed H, Kassem S, et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. *Thromb Res.* 2010;125(6):e259-264. Exclude: Publication type-not randomized control trial.

922. Wells QS, Delaney JT, Roden DM. Genetic determinants of response to cardiovascular drugs. *Current Opinion in Cardiology.* 2012;27(3):253-261. Exclude: Publication type-commentary.

923. Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. *Clinical Pharmacology & Therapeutics.* 2008;84(1):83-89. Exclude: Not intervention of interest.

924. Werner D, Werner U, Wuerfel A, et al. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. *European Journal of Clinical Pharmacology.* 2009;65(8):783-788. Exclude: Not intervention of interest.

925. Weston BW, Monahan PE. Familial deficiency of vitamin K-dependent clotting factors. *Haemophilia.* 2008;14(6):1209-1213. Exclude: Publication type-commentary.

926. Wheeler MT, Ho M, Knowles JW, Pavlovic A, Ashley EA. Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics. *Journal of Cardiovascular Translational Research.* 2008;1(1):25-36. Exclude: Publication type-commentary.

927. White PJ. Patient factors that influence warfarin dose response. *Journal of Pharmacy Practice.* 2010;23(3):194-204. Exclude: Publication type-commentary.

928. Wilding G, Blumberg ES, Vesell ES. Reduced warfarin binding of albumin variants. *Science.* 1977;195(4282):991-994. Exclude: Date.

929. Wiley LK, Vanhouten JP, Samuels DC, et al. Strategies for Equitable Pharmacogenomic-Guided Warfarin Dosing among European and African American Individuals in a Clinical Population. *Pacific Symposium on Biocomputing.* 2017;22:545-556. Exclude: No outcome of interest.

930. Wilke RA, Berg RL, Vidaillet HJ, Caldwell MD, Burmester JK, Hillman MA. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. *Clinical Medicine & Research.* 2005;3(4):207-213. Exclude: Publication type-not randomized control trial.

931. Williams LA, 3rd, Hunter JM, Jr., Marques MB, Vetter TR. Periprocedural management of patients on anticoagulants. *Clinics in Laboratory Medicine.* 2014;34(3):595-611. Exclude: Not intervention of interest.

932. Wittkowsky AK. Pharmacogenomics and the management of oral anticoagulation. *Current Hematology Reports.* 2004;3(5):363-367. Exclude: Date.

933. Wiwanitkit V. Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. *Clinical & Applied Thrombosis/Hemostasis.* 2006;12(2):219-222. Exclude: Not intervention of interest.

934. Wolkanin-Bartnik J, Pogorzelska H, Szperl M, Bartnik A, Koziarek J, Bilinska ZT. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. *Pharmacogenetics and Genomics*. 2013;23(11):611-618. Exclude: Publication type-not randomized control trial.

935. Woodcock J, Lesko LJ. Pharmacogenetics--tailoring treatment for the outliers. *New England Journal of Medicine*. 2009;360(8):811-813. Exclude: Publication type-commentary.

936. Wright GE. Warfarin pharmacogenetics in the era of new oral anticoagulants. *Clinical Genetics*. 2015;88(2):135-136. Exclude: Publication type-commentary.

937. Wu AC, Fuhlbrigge AL. Economic evaluation of pharmacogenetic tests. *Clinical Pharmacology & Therapeutics*. 2008;84(2):272-274. Exclude: Publication type-commentary.

938. Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. *Pharmacogenomics*. 2007;8(7):851-861. Exclude: Publication type-commentary.

939. Wu AH. Pharmacogenomic testing for warfarin dosing: we are ready now. *Expert Review of Cardiovascular Therapy*. 2009;7(12):1483-1485. Exclude: Publication type-commentary.

940. Wu AH. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. *Archives of Pathology & Laboratory Medicine*. 2013;137(9):1232-1236. Exclude: Publication type-not randomized control trial.

941. Wu AH. Pharmacogenomic testing and response to warfarin. *Lancet*. 2015;385(9984):2231-2232. Exclude: Publication type-commentary.

942. Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. *Pharmacogenomics*. 2008;9(2):169-178. Exclude: Publication type-not randomized control trial.

943. Wypasek E, Branicka A, Awsiuk M, Sadowski J, Undas A. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. *Thromb Res*. 2014;134(3):604-609. Exclude: Publication type-not randomized control trial.

944. Wypasek E, Ciesla M, Suder B, Janik L, Sadowski J, Undas A. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement. *Advances in Clinical & Experimental Medicine*. 2015;24(4):607-614. Exclude: Not intervention of interest.

945. Wypasek E, Mazur P, Bochenek M, et al. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up. *Journal of Physiology & Pharmacology*. 2016;67(3):385-393. Exclude: Publication type-not randomized control trial.

946. Xu H, Jiang M, Oetjens M, et al. Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. *Journal of the American Medical Informatics Association*. 2011;18(4):387-391. Exclude: Publication type-not randomized control trial.

947. Xu H, Su S, Tang W, et al. Comparison of the Performance of the Warfarin Pharmacogenetics Algorithms in Patients with Surgery of Heart Valve Replacement and Heart Valvuloplasty. *Thromb Res*. 2015;136(3):552-559. Exclude: Not intervention of interest.

948. Xu H, Xie X, Wang B, et al. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. *International Journal of Cardiology*. 2014;177(2):654-657. Exclude: Publication type-letter.

949. Xu Q, Xu B, Zhang Y, et al. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. *Thromb Haemost*. 2012;108(6):1132-1140. Exclude: Not intervention of interest.

950. Xue L, Holford N, Ding XL, et al. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.[Erratum appears in Br J Clin Pharmacol. 2017 Jul;83(7):1602; PMID: 28597521]. *British Journal of Clinical Pharmacology*. 2017;83(4):823-835. Exclude: Publication type-not randomized control trial.

951. Yamamoto I, Azuma J. [Individualization of drug therapy and pharmacogenetics]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*. 1998;56(3):579-583. Exclude: Date.

952. Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, Shimada T. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. *Archives of Biochemistry & Biophysics*. 1997;342(2):329-337. Exclude: Not intervention of interest.

953. Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. *Biochemical Pharmacology*. 1998;56(2):243-251. Exclude: Not intervention of interest.

954. Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. *Xenobiotica*. 1998;28(2):103-115. Exclude: Date.

955. Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. *International Journal of Cardiology*. 2013;168(4):4234-4243. Exclude: Not intervention of interest.

956. Yang L, Manithody C, Rezaie AR. Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases. *Blood*. 2004;104(6):1753-1759. Exclude: Date.

957. Yang S, Xu L, Wu HM. Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry. *Journal of Molecular Diagnostics*. 2010;12(2):162-168. Exclude: Publication type-not randomized control trial.

958. Yang Y, Peter I, Scott SA. Pharmacogenetics in Jewish populations. *Drug Metabolism & Drug Interactions*. 2014;29(4):221-233. Exclude: Publication type-commentary.

959. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. *European Journal of Clinical Pharmacology*. 2001;57(10):729-735. Exclude: Date.

960. Yegneswaran S, Kojima Y, Nguyen PM, Gale AJ, Heeb MJ, Griffin JH. Factor Va residues 311-325 represent an activated protein C binding region. *Journal of Biological Chemistry*. 2007;282(39):28353-28361. Exclude: Publication type-not randomized control trial.

961. Yin T, Hanada H, Miyashita K, et al. No association between vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) and the variability of warfarin dose requirement in a Japanese patient population. *Thromb Res*. 2008;122(2):179-184. Exclude: Publication type-not randomized control trial.

962. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. *Thromb Res*. 2007;120(1):1-10. Exclude: Publication type-commentary.

963. Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders. *American Journal of Cardiovascular Drugs*. 2013;13(3):151-162. Exclude: Publication type-commentary.

964. Yokota H, Satoh Y, Ono Y, et al. [Establishment of a pharmacogenomic testing system for the realization of individual pharmacotherapy]. *Rinsho Byori - Japanese Journal of Clinical Pathology*. 2008;56(9):772-780. Exclude: Not English.

965. You JH. Anticoagulation: improve care quality or use new alternatives? *Lancet*. 2011;377(9764):464-465; author reply 465. Exclude: Publication type-commentary.

966. You JH. Pharmacoeconomic evaluation of warfarin pharmacogenomics. *Expert Opinion on Pharmacotherapy*. 2011;12(3):435-441. Exclude: Publication type-not systematic review.

967. You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. *Pharmacogenetics and Genomics*. 2014;24(1):6-14. Exclude: No comparator.

968. You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. *Thromb Haemost*. 2004;92(3):590-597. Exclude: Date.

969. You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. *J Thromb Thrombolys*. 2011;31(1):113-118. Exclude: Not intervention of interest.

970. You JH, Zuo Z, Lo CM, et al. Any effect of CYP2C9 variants on warfarin clearance in Chinese patients? *Thromb Haemost*. 2007;97(5):866-868. Exclude: Publication type-letter.

971. Yu LP, Song HT, Zeng ZY, Wang QM, Qiu HF. [Validation and comparison of pharmacogenetics-based warfarin dosing algorithms in Han Chinese patients]. *Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]*. 2012;40(7):614-619. Exclude: Not English.

972. Yu WY, Sun X, Wadelius M, et al. Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis. *Cardiovascular therapeutics*. 2016;34(5):297-307. Exclude: Not intervention of interest.

973. Zaiou M, El Amri H. Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine. *Clinical Genetics*. 2017;91(3):355-370. Exclude: Publication type-commentary.

974. Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. *Pharmacogenomics*. 2011;12(1):15-25. Exclude: Publication type-not randomized control trial.

975. Zeidler EM, Goetz AE, Zollner C. [Pharmacogenetics. Clinical relevance in anesthsiology]. *Anaesthesist*. 2013;62(11):874-886. Exclude: Not English.

976. Zhang H, Ma K, Liu W, Yang F, Liu J, Zhou H. Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation. *Gene*. 2016;591(1):80-84. Exclude: Publication type-not randomized control trial.

977. Zhang J, Tian L, Huang J, Huang S, Chai T, Shen J. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. *Cardiovascular therapeutics*. 2017;35(1):26-32. Exclude: Not intervention of interest.

978. Zhang W, Zhang WJ, Zhu J, et al. Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. *Pharmacogenomics*. 2012;13(3):309-321. Exclude: Publication type-not randomized control trial.

979. Zhang X, Li L, Ding X, Kaminsky LS. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. *Drug Metabolism & Disposition*. 2011;39(8):1433-1439. Exclude: Publication type-not randomized control trial.

980. Zhao L, Chen C, Li B, et al. Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement. *PLoS ONE [Electronic Resource]*. 2014;9(4):e94573. Exclude: Publication type-not randomized control trial.

981. Zhe X, Zhang SY, Hu R, et al. A double-blind, randomized controlled trial of genotype-based warfarin initiation in patients with mechanical heart valves. *Journal of the american college of cardiology*. 2016;Conference: 27th great wall international congress of cardiology, 21st annual scientific meeting of the international society of cardiovascular pharmacotherapy international congress of cardiovascular prevention and rehabilitation. 2016. China. Conference start: 20161013. Conference end: 20161016 68(16 Supplement):C46. Exclude: Publication type-conference abstract.

982. Zhong SL, Liu Y, Yu XY, et al. The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. *European*

Journal of Clinical Pharmacology. 2011;67(6):581-590. Exclude: Publication type-not randomized control trial.

983. Zhong SL, Yu XY, Liu Y, et al. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. *Pharmacogenetics and Genomics*. 2012;22(3):176-182. Exclude: Publication type-not randomized control trial.

984. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. *Current Drug Metabolism*. 2008;9(8):738-784. Exclude: Publication type-commentary.

985. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. *Toxicology*. 2010;278(2):165-188. Exclude: Publication type-commentary.

986. Zhu J, Zhang W, Li Y, et al. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. *Pharmacogenomics*. 2010;11(1):113-119. Exclude: Publication type-not randomized control trial.

987. Zhuang B, Han J, Xiang G, et al. A fully integrated and automated microsystem for rapid pharmacogenetic typing of multiple warfarin-related single-nucleotide polymorphisms. *Lab on a Chip*. 2016;16(1):86-95. Exclude: Not intervention of interest.

988. Zineh I, Johnson JA. Pharmacogenetics of chronic cardiovascular drugs: applications and implications. *Expert Opinion on Pharmacotherapy*. 2006;7(11):1417-1427. Exclude: Date.

989. Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing--recalibrating expectations. *New England Journal of Medicine*. 2013;369(24):2273-2275. Exclude: Publication type-commentary.